ONTOLOGY REPORT - ANNOTATIONS
| Term: | cyclophosphamide |
|
| Accession: | CHEBI:4027
|
browse the term
|
| Definition: | A cyclic phosphorodiamide-based nitrogen mustard. |
| Synonyms: | exact_synonym: | N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide |
| | related_synonym: | (RS)-Cyclophosphamide; 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; C7H15Cl2N2O2P; ClCCN(CCCl)P1(=O)NCCCO1; Cyclophosphamide anhydrous; InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12); InChIKey=CMSMOCZEIVJLDB-UHFFFAOYSA-N; N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide |
| | xref_casrn: | 50-18-0 |
| | xref: | Beilstein:11744 "Beilstein Registry Number"; ChEMBL:108417 "ChEMBL COMPOUND"; ChemIDplus:50-18-0 "CAS Registry Number"; DrugBank:DB00531 "DrugBank"; KEGG COMPOUND:50-18-0 "CAS Registry Number"; KEGG COMPOUND:C07888 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D003520 |
| | xref: | NIST Chemistry WebBook:50-18-0 "CAS Registry Number"; Wikipedia:Cyclophosphamide "Wikipedia" |
|
|
cyclophosphamide
|
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
multiple interactions |
EXP |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
multiple interactions |
EXP |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
increases expression |
EXP |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
decreases expression |
ISO |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCC1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
multiple interactions |
EXP |
16 |
16,043,434 |
16,236,931 |
RGD:6480464 |
CTD |
| G |
ABCC1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
decreases response to substance |
EXP |
16 |
16,043,434 |
16,236,931 |
RGD:6480464 |
CTD |
| G |
ABCG2 |
ATP-binding cassette, sub-family G (WHITE), member 2 |
|
multiple interactions |
EXP |
4 |
89,011,416 |
89,152,474 |
RGD:6480464 |
CTD |
| G |
ABHD3 |
abhydrolase domain containing 3 |
|
increases expression |
EXP |
18 |
19,230,858 |
19,284,766 |
RGD:6480464 |
CTD |
| G |
ACTB |
actin, beta |
|
decreases expression |
EXP |
7 |
5,566,779 |
5,570,232 |
RGD:6480464 |
CTD |
| G |
ACTB |
actin, beta |
|
affects expression |
ISO |
7 |
5,566,779 |
5,570,232 |
RGD:6480464 |
CTD |
| G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 (pituitary) |
|
increases expression |
ISO |
18 |
904,944 |
912,173 |
RGD:6480464 |
CTD |
| G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 (pituitary) |
|
affects expression |
ISO |
18 |
904,944 |
912,173 |
RGD:6480464 |
CTD |
| G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 (pituitary) |
|
increases expression |
ISO |
18 |
904,944 |
912,173 |
RGD:6480464 |
CTD |
| G |
ADCYAP1R1 |
adenylate cyclase activating polypeptide 1 (pituitary) receptor type I |
|
affects expression |
ISO |
7 |
31,092,076 |
31,151,093 |
RGD:6480464 |
CTD |
| G |
ADM |
adrenomedullin |
|
affects response to substance |
EXP |
11 |
10,326,642 |
10,328,923 |
RGD:6480464 |
CTD |
| G |
AFP |
alpha-fetoprotein |
|
affects expression |
ISO |
4 |
74,301,933 |
74,321,492 |
RGD:6480464 |
CTD |
| G |
AGL |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
|
affects response to substance |
EXP |
1 |
100,315,640 |
100,389,579 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
ALAD |
aminolevulinate dehydratase |
|
multiple interactions |
EXP |
9 |
116,148,592 |
116,163,618 |
RGD:6480464 |
CTD |
| G |
ALCAM |
activated leukocyte cell adhesion molecule |
|
increases expression |
ISO |
3 |
105,085,557 |
105,295,757 |
RGD:6480464 |
CTD |
| G |
ALDH1A1 |
aldehyde dehydrogenase 1 family, member A1 |
|
affects response to substance |
EXP |
9 |
75,515,578 |
75,568,233 |
RGD:6480464 |
CTD |
| G |
ALDH1A1 |
aldehyde dehydrogenase 1 family, member A1 |
|
decreases response to substance |
EXP |
9 |
75,515,578 |
75,568,233 |
RGD:6480464 |
CTD |
| G |
ALDH1A1 |
aldehyde dehydrogenase 1 family, member A1 |
|
increases expression |
EXP |
9 |
75,515,578 |
75,568,233 |
RGD:6480464 |
CTD |
| G |
ALDH2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
increases expression |
EXP |
12 |
112,204,691 |
112,247,789 |
RGD:6480464 |
CTD |
| G |
ALDH3A1 |
aldehyde dehydrogenase 3 family, member A1 |
|
affects response to substance |
EXP |
17 |
19,641,297 |
19,651,746 |
RGD:6480464 |
CTD |
| G |
ALOX5AP |
arachidonate 5-lipoxygenase-activating protein |
|
decreases expression |
EXP |
13 |
31,287,615 |
31,338,565 |
RGD:6480464 |
CTD |
| G |
ALYREF |
Aly/REF export factor |
|
decreases expression |
ISO |
17 |
79,845,711 |
79,849,462 |
RGD:6480464 |
CTD |
| G |
AMFR |
autocrine motility factor receptor, E3 ubiquitin protein ligase |
|
multiple interactions |
EXP |
16 |
56,395,364 |
56,459,450 |
RGD:6480464 |
CTD |
| G |
ANGPT1 |
angiopoietin 1 |
|
increases expression |
EXP |
8 |
108,261,710 |
108,510,254 |
RGD:6480464 |
CTD |
| G |
APEX1 |
APEX nuclease (multifunctional DNA repair enzyme) 1 |
|
increases expression |
ISO |
14 |
20,923,290 |
20,925,931 |
RGD:6480464 |
CTD |
| G |
APOB |
apolipoprotein B (including Ag(x) antigen) |
|
decreases expression |
ISO |
2 |
21,224,301 |
21,266,945 |
RGD:6480464 |
CTD |
| G |
APOE |
apolipoprotein E |
|
decreases expression |
ISO |
19 |
45,409,039 |
45,412,650 |
RGD:6480464 |
CTD |
| G |
APOE |
apolipoprotein E |
|
increases expression |
ISO |
19 |
45,409,039 |
45,412,650 |
RGD:6480464 |
CTD |
| G |
ARG1 |
arginase, liver |
|
increases expression |
ISO |
6 |
131,894,344 |
131,905,472 |
RGD:6480464 |
CTD |
| G |
ARG1 |
arginase, liver |
|
affects expression |
ISO |
6 |
131,894,344 |
131,905,472 |
RGD:6480464 |
CTD |
| G |
ARG1 |
arginase, liver |
|
decreases expression |
ISO |
6 |
131,894,344 |
131,905,472 |
RGD:6480464 |
CTD |
| G |
ARHGDIB |
Rho GDP dissociation inhibitor (GDI) beta |
|
increases expression |
EXP |
12 |
15,094,950 |
15,114,562 |
RGD:6480464 |
CTD |
| G |
ARHGEF26 |
Rho guanine nucleotide exchange factor (GEF) 26 |
|
increases expression |
EXP |
3 |
153,838,792 |
153,975,616 |
RGD:6480464 |
CTD |
| G |
ATF2 |
activating transcription factor 2 |
|
increases expression |
ISO |
2 |
175,936,978 |
176,032,934 |
RGD:6480464 |
CTD |
| G |
ATF5 |
activating transcription factor 5 |
|
decreases expression |
EXP |
19 |
50,431,959 |
50,437,193 |
RGD:6480464 |
CTD |
| G |
ATG3 |
autophagy related 3 |
|
decreases expression |
EXP |
3 |
112,251,359 |
112,280,485 |
RGD:6480464 |
CTD |
| G |
AURKB |
aurora kinase B |
|
increases expression |
ISO |
17 |
8,108,049 |
8,113,944 |
RGD:6480464 |
CTD |
| G |
AXL |
AXL receptor tyrosine kinase |
|
increases expression |
EXP |
19 |
41,725,108 |
41,767,671 |
RGD:6480464 |
CTD |
| G |
B3GALNT2 |
beta-1,3-N-acetylgalactosaminyltransferase 2 |
|
increases expression |
EXP |
1 |
235,610,533 |
235,667,781 |
RGD:6480464 |
CTD |
| G |
BAD |
BCL2-associated agonist of cell death |
|
increases expression |
ISO |
11 |
64,037,300 |
64,052,176 |
RGD:6480464 |
CTD |
| G |
BAG1 |
BCL2-associated athanogene |
|
multiple interactions |
EXP |
9 |
33,252,469 |
33,264,759 |
RGD:6480464 |
CTD |
| G |
BBS4 |
Bardet-Biedl syndrome 4 |
|
multiple interactions |
EXP |
15 |
72,978,520 |
73,030,817 |
RGD:6480464 |
CTD |
| G |
BCHE |
butyrylcholinesterase |
|
multiple interactions |
EXP |
3 |
165,490,692 |
165,555,253 |
RGD:6480464 |
CTD |
| G |
BCHE |
butyrylcholinesterase |
|
decreases activity |
EXP |
3 |
165,490,692 |
165,555,253 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L2 |
BCL2-like 2 |
|
increases expression |
ISO |
14 |
23,775,971 |
23,780,968 |
RGD:6480464 |
CTD |
| G |
BCL6 |
B-cell CLL/lymphoma 6 |
|
decreases expression |
ISO |
3 |
187,439,165 |
187,463,513 |
RGD:6480464 |
CTD |
| G |
BDH1 |
3-hydroxybutyrate dehydrogenase, type 1 |
|
affects response to substance |
EXP |
3 |
197,236,654 |
197,300,194 |
RGD:6480464 |
CTD |
| G |
BDKRB1 |
bradykinin receptor B1 |
|
increases expression |
ISO |
14 |
96,722,547 |
96,731,100 |
RGD:6480464 |
CTD |
| G |
BDKRB1 |
bradykinin receptor B1 |
|
increases expression |
ISO |
14 |
96,722,547 |
96,731,100 |
RGD:6480464 |
CTD |
| G |
BDKRB2 |
bradykinin receptor B2 |
|
affects expression |
ISO |
14 |
96,671,135 |
96,710,666 |
RGD:6480464 |
CTD |
| G |
BDNF |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
11 |
27,676,440 |
27,743,605 |
RGD:6480464 |
CTD |
| G |
BECN1 |
beclin 1, autophagy related |
|
multiple interactions |
EXP |
17 |
40,962,150 |
40,976,310 |
RGD:6480464 |
CTD |
| G |
BIK |
BCL2-interacting killer (apoptosis-inducing) |
|
decreases expression |
EXP |
22 |
43,506,754 |
43,525,718 |
RGD:6480464 |
CTD |
| G |
BLVRB |
biliverdin reductase B (flavin reductase (NADPH)) |
|
decreases expression |
ISO |
19 |
40,953,691 |
40,971,725 |
RGD:6480464 |
CTD |
| G |
BPI |
bactericidal/permeability-increasing protein |
|
decreases expression |
EXP |
20 |
36,932,552 |
36,965,905 |
RGD:6480464 |
CTD |
| G |
BSCL2 |
Berardinelli-Seip congenital lipodystrophy 2 (seipin) |
|
increases expression |
ISO |
11 |
62,457,734 |
62,477,091 |
RGD:6480464 |
CTD |
| G |
BSG |
basigin (Ok blood group) |
|
decreases expression |
ISO |
19 |
571,277 |
583,493 |
RGD:6480464 |
CTD |
| G |
BTG1 |
B-cell translocation gene 1, anti-proliferative |
|
decreases expression |
ISO |
12 |
92,534,054 |
92,539,673 |
RGD:6480464 |
CTD |
| G |
BTG3 |
BTG family, member 3 |
|
multiple interactions |
EXP |
21 |
18,965,968 |
18,985,268 |
RGD:6480464 |
CTD |
| G |
BUB3 |
BUB3 mitotic checkpoint protein |
|
multiple interactions |
EXP |
10 |
124,913,760 |
124,924,886 |
RGD:6480464 |
CTD |
| G |
C1QA |
complement component 1, q subcomponent, A chain |
|
increases expression |
ISO |
1 |
22,963,118 |
22,966,175 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
increases expression |
ISO |
19 |
6,677,846 |
6,720,662 |
RGD:6480464 |
CTD |
| G |
CA12 |
carbonic anhydrase XII |
|
multiple interactions |
EXP |
15 |
63,615,730 |
63,674,075 |
RGD:6480464 |
CTD |
| G |
CA2 |
carbonic anhydrase II |
|
decreases expression |
EXP |
8 |
86,376,131 |
86,393,721 |
RGD:6480464 |
CTD |
| G |
CA2 |
carbonic anhydrase II |
|
increases expression |
ISO |
8 |
86,376,131 |
86,393,721 |
RGD:6480464 |
CTD |
| G |
CABP1 |
calcium binding protein 1 |
|
decreases expression |
ISO |
12 |
121,078,422 |
121,105,127 |
RGD:6480464 |
CTD |
| G |
CABP1 |
calcium binding protein 1 |
|
decreases expression |
ISO |
12 |
121,078,422 |
121,105,127 |
RGD:6480464 |
CTD |
| G |
CABP2 |
calcium binding protein 2 |
|
decreases expression |
ISO |
11 |
67,286,418 |
67,290,899 |
RGD:6480464 |
CTD |
| G |
CALR |
calreticulin |
|
decreases expression |
ISO |
19 |
13,049,414 |
13,055,304 |
RGD:6480464 |
CTD |
| G |
CALR |
calreticulin |
|
increases expression |
ISO |
19 |
13,049,414 |
13,055,304 |
RGD:6480464 |
CTD |
| G |
CALR |
calreticulin |
|
decreases expression |
ISO |
19 |
13,049,414 |
13,055,304 |
RGD:6480464 |
CTD |
| G |
CANX |
calnexin |
|
decreases expression |
ISO |
5 |
179,125,930 |
179,158,642 |
RGD:6480464 |
CTD |
| G |
CAPN2 |
calpain 2, (m/II) large subunit |
|
increases expression |
ISO |
1 |
223,889,295 |
223,963,720 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
decreases expression |
EXP |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
increases expression |
ISO |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
decreases response to substance |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases expression |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
affects activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
affects activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CCIN |
calicin |
|
increases expression |
EXP |
9 |
36,169,389 |
36,171,331 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL25 |
chemokine (C-C motif) ligand 25 |
|
decreases expression |
ISO |
19 |
8,117,646 |
8,127,547 |
RGD:6480464 |
CTD |
| G |
CCL7 |
chemokine (C-C motif) ligand 7 |
|
increases expression |
ISO |
17 |
32,597,240 |
32,599,256 |
RGD:6480464 |
CTD |
| G |
CCL7 |
chemokine (C-C motif) ligand 7 |
|
increases expression |
ISO |
17 |
32,597,240 |
32,599,256 |
RGD:6480464 |
CTD |
| G |
CCL7 |
chemokine (C-C motif) ligand 7 |
|
increases expression |
ISO |
17 |
32,597,240 |
32,599,256 |
RGD:6480464 |
CTD |
| G |
CCL8 |
chemokine (C-C motif) ligand 8 |
|
increases expression |
ISO |
17 |
32,646,066 |
32,648,421 |
RGD:6480464 |
CTD |
| G |
CCNA2 |
cyclin A2 |
|
decreases expression |
ISO |
4 |
122,737,599 |
122,745,088 |
RGD:6480464 |
CTD |
| G |
CCND2 |
cyclin D2 |
|
increases expression |
ISO |
12 |
4,382,902 |
4,414,522 |
RGD:6480464 |
CTD |
| G |
CCND3 |
cyclin D3 |
|
decreases expression |
ISO |
6 |
41,902,671 |
42,016,610 |
RGD:6480464 |
CTD |
| G |
CCR5 |
chemokine (C-C motif) receptor 5 (gene/pseudogene) |
|
increases expression |
ISO |
3 |
46,411,633 |
46,417,697 |
RGD:6480464 |
CTD |
| G |
CCR8 |
chemokine (C-C motif) receptor 8 |
|
decreases expression |
EXP |
3 |
39,371,197 |
39,375,171 |
RGD:6480464 |
CTD |
| G |
CCR9 |
chemokine (C-C motif) receptor 9 |
|
decreases expression |
ISO |
3 |
45,927,996 |
45,944,667 |
RGD:6480464 |
CTD |
| G |
CCT3 |
chaperonin containing TCP1, subunit 3 (gamma) |
|
decreases expression |
ISO |
1 |
156,278,752 |
156,308,206 |
RGD:6480464 |
CTD |
| G |
CCT5 |
chaperonin containing TCP1, subunit 5 (epsilon) |
|
decreases expression |
ISO |
5 |
10,250,282 |
10,266,501 |
RGD:6480464 |
CTD |
| G |
CCT7 |
chaperonin containing TCP1, subunit 7 (eta) |
|
decreases expression |
ISO |
2 |
73,461,364 |
73,480,150 |
RGD:6480464 |
CTD |
| G |
CD14 |
CD14 molecule |
|
increases expression |
ISO |
5 |
140,011,313 |
140,013,286 |
RGD:6480464 |
CTD |
| G |
CD14 |
CD14 molecule |
|
increases expression |
ISO |
5 |
140,011,313 |
140,013,286 |
RGD:6480464 |
CTD |
| G |
CD14 |
CD14 molecule |
|
increases expression |
ISO |
5 |
140,011,313 |
140,013,286 |
RGD:6480464 |
CTD |
| G |
CD151 |
CD151 molecule (Raph blood group) |
|
increases expression |
ISO |
11 |
832,952 |
838,835 |
RGD:6480464 |
CTD |
| G |
CD2 |
CD2 molecule |
|
decreases expression |
ISO |
1 |
117,297,086 |
117,311,851 |
RGD:6480464 |
CTD |
| G |
CD27 |
CD27 molecule |
|
decreases expression |
ISO |
12 |
6,554,051 |
6,560,884 |
RGD:6480464 |
CTD |
| G |
CD28 |
CD28 molecule |
|
decreases expression |
ISO |
2 |
204,571,198 |
204,603,635 |
RGD:6480464 |
CTD |
| G |
CD38 |
CD38 molecule |
|
increases expression |
ISO |
4 |
15,779,931 |
15,850,706 |
RGD:6480464 |
CTD |
| G |
CD3D |
CD3d molecule, delta (CD3-TCR complex) |
|
decreases expression |
ISO |
11 |
118,209,789 |
118,213,459 |
RGD:6480464 |
CTD |
| G |
CD3E |
CD3e molecule, epsilon (CD3-TCR complex) |
|
decreases expression |
ISO |
11 |
118,175,295 |
118,186,890 |
RGD:6480464 |
CTD |
| G |
CD3G |
CD3g molecule, gamma (CD3-TCR complex) |
|
decreases expression |
ISO |
11 |
118,215,059 |
118,224,497 |
RGD:6480464 |
CTD |
| G |
CD4 |
CD4 molecule |
|
decreases expression |
ISO |
12 |
6,898,638 |
6,929,976 |
RGD:6480464 |
CTD |
| G |
CD40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
decreases expression |
ISO |
20 |
44,746,906 |
44,758,384 |
RGD:6480464 |
CTD |
| G |
CD5 |
CD5 molecule |
|
decreases expression |
ISO |
11 |
60,869,930 |
60,895,324 |
RGD:6480464 |
CTD |
| G |
CD6 |
CD6 molecule |
|
decreases expression |
ISO |
11 |
60,739,113 |
60,787,849 |
RGD:6480464 |
CTD |
| G |
CD69 |
CD69 molecule |
|
decreases expression |
ISO |
12 |
9,905,082 |
9,913,497 |
RGD:6480464 |
CTD |
| G |
CD74 |
CD74 molecule, major histocompatibility complex, class II invariant chain |
|
decreases expression |
ISO |
5 |
149,781,200 |
149,792,499 |
RGD:6480464 |
CTD |
| G |
CD79B |
CD79b molecule, immunoglobulin-associated beta |
|
decreases expression |
ISO |
17 |
62,006,098 |
62,009,704 |
RGD:6480464 |
CTD |
| G |
CD83 |
CD83 molecule |
|
decreases expression |
ISO |
6 |
14,117,487 |
14,137,149 |
RGD:6480464 |
CTD |
| G |
CD8A |
CD8a molecule |
|
decreases expression |
ISO |
2 |
87,011,728 |
87,035,519 |
RGD:6480464 |
CTD |
| G |
CD8B |
CD8b molecule |
|
decreases expression |
ISO |
2 |
87,042,460 |
87,089,047 |
RGD:6480464 |
CTD |
| G |
CDC20 |
cell division cycle 20 |
|
increases expression |
ISO |
1 |
43,824,626 |
43,828,874 |
RGD:6480464 |
CTD |
| G |
CDH1 |
cadherin 1, type 1, E-cadherin (epithelial) |
|
affects expression |
ISO |
16 |
68,771,195 |
68,869,444 |
RGD:6480464 |
CTD |
| G |
CDH2 |
cadherin 2, type 1, N-cadherin (neuronal) |
|
affects expression |
ISO |
18 |
25,530,930 |
25,757,445 |
RGD:6480464 |
CTD |
| G |
CDH3 |
cadherin 3, type 1, P-cadherin (placental) |
|
affects expression |
ISO |
16 |
68,678,151 |
68,732,957 |
RGD:6480464 |
CTD |
| G |
CDK2 |
cyclin-dependent kinase 2 |
|
decreases expression |
ISO |
12 |
56,360,556 |
56,366,568 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
EXP |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1B |
cyclin-dependent kinase inhibitor 1B (p27, Kip1) |
|
multiple interactions |
EXP |
12 |
12,870,302 |
12,875,305 |
RGD:6480464 |
CTD |
| G |
CDKN1C |
cyclin-dependent kinase inhibitor 1C (p57, Kip2) |
|
increases expression |
ISO |
11 |
2,904,448 |
2,906,995 |
RGD:6480464 |
CTD |
| G |
CDKN2D |
cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) |
|
decreases expression |
ISO |
19 |
10,677,138 |
10,679,655 |
RGD:6480464 |
CTD |
| G |
CEL |
carboxyl ester lipase |
|
increases expression |
EXP |
9 |
135,937,365 |
135,947,248 |
RGD:6480464 |
CTD |
| G |
CFB |
complement factor B |
|
increases expression |
ISO |
6 |
31,913,721 |
31,919,861 |
RGD:6480464 |
CTD |
| G |
CFI |
complement factor I |
|
affects response to substance |
EXP |
4 |
110,661,848 |
110,723,335 |
RGD:6480464 |
CTD |
| G |
CHGA |
chromogranin A (parathyroid secretory protein 1) |
|
decreases expression |
ISO |
14 |
93,389,445 |
93,401,638 |
RGD:6480464 |
CTD |
| G |
CHRM5 |
cholinergic receptor, muscarinic 5 |
|
increases expression |
ISO |
15 |
34,261,089 |
34,357,287 |
RGD:6480464 |
CTD |
| G |
CITED2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
affects expression |
ISO |
6 |
139,693,392 |
139,695,787 |
RGD:6480464 |
CTD |
| G |
CITED2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
decreases expression |
ISO |
6 |
139,693,392 |
139,695,787 |
RGD:6480464 |
CTD |
| G |
CLIC4 |
chloride intracellular channel 4 |
|
increases expression |
ISO |
1 |
25,071,760 |
25,170,815 |
RGD:6480464 |
CTD |
| G |
COCH |
coagulation factor C homolog, cochlin (Limulus polyphemus) |
|
affects response to substance |
EXP |
14 |
31,343,741 |
31,359,822 |
RGD:6480464 |
CTD |
| G |
COMT |
catechol-O-methyltransferase |
|
increases expression |
ISO |
22 |
19,929,263 |
19,957,498 |
RGD:6480464 |
CTD |
| G |
COX7A2 |
cytochrome c oxidase subunit VIIa polypeptide 2 (liver) |
|
decreases expression |
EXP |
6 |
75,947,391 |
75,953,644 |
RGD:6480464 |
CTD |
| G |
CRABP2 |
cellular retinoic acid binding protein 2 |
|
increases expression |
EXP |
1 |
156,669,398 |
156,675,608 |
RGD:6480464 |
CTD |
| G |
CREB1 |
cAMP responsive element binding protein 1 |
|
increases expression |
ISO |
2 |
208,394,616 |
208,470,284 |
RGD:6480464 |
CTD |
| G |
CREM |
cAMP responsive element modulator |
|
decreases expression |
ISO |
10 |
35,415,769 |
35,501,886 |
RGD:6480464 |
CTD |
| G |
CREM |
cAMP responsive element modulator |
|
multiple interactions |
ISO |
10 |
35,415,769 |
35,501,886 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases expression |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases expression |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases expression |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRHR2 |
corticotropin releasing hormone receptor 2 |
|
increases expression |
ISO |
7 |
30,691,559 |
30,739,719 |
RGD:6480464 |
CTD |
| G |
CSF1 |
colony stimulating factor 1 (macrophage) |
|
multiple interactions |
ISO |
1 |
110,453,233 |
110,473,616 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
affects activity |
EXP |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
increases expression |
ISO |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSK |
c-src tyrosine kinase |
|
decreases expression |
ISO |
15 |
75,074,425 |
75,095,539 |
RGD:6480464 |
CTD |
| G |
CST7 |
cystatin F (leukocystatin) |
|
decreases expression |
EXP |
20 |
24,929,866 |
24,940,564 |
RGD:6480464 |
CTD |
| G |
CTNNBIP1 |
catenin, beta interacting protein 1 |
|
multiple interactions |
EXP |
1 |
9,908,334 |
9,970,316 |
RGD:6480464 |
CTD |
| G |
CTNND2 |
catenin (cadherin-associated protein), delta 2 |
|
multiple interactions |
EXP |
5 |
10,971,952 |
11,904,110 |
RGD:6480464 |
CTD |
| G |
CTSD |
cathepsin D |
|
multiple interactions |
ISO |
11 |
1,773,982 |
1,785,222 |
RGD:6480464 |
CTD |
| G |
CTSH |
cathepsin H |
|
increases expression |
EXP |
15 |
79,214,092 |
79,237,420 |
RGD:6480464 |
CTD |
| G |
CTSL1 |
cathepsin L1 |
|
increases expression |
EXP |
9 |
90,340,974 |
90,346,384 |
RGD:6480464 |
CTD |
| G |
CX3CL1 |
chemokine (C-X3-C motif) ligand 1 |
|
increases expression |
ISO |
16 |
57,406,414 |
57,418,956 |
RGD:6480464 |
CTD |
| G |
CX3CR1 |
chemokine (C-X3-C motif) receptor 1 |
|
increases expression |
ISO |
3 |
39,304,985 |
39,323,226 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL10 |
chemokine (C-X-C motif) ligand 10 |
|
affects expression |
ISO |
4 |
76,942,269 |
76,944,689 |
RGD:6480464 |
CTD |
| G |
CXCL10 |
chemokine (C-X-C motif) ligand 10 |
|
increases response to substance |
ISO |
4 |
76,942,269 |
76,944,689 |
RGD:6480464 |
CTD |
| G |
CXCL10 |
chemokine (C-X-C motif) ligand 10 |
|
increases expression |
ISO |
4 |
76,942,269 |
76,944,689 |
RGD:6480464 |
CTD |
| G |
CXCL11 |
chemokine (C-X-C motif) ligand 11 |
|
increases expression |
ISO |
4 |
76,954,835 |
76,957,350 |
RGD:6480464 |
CTD |
| G |
CXCL11 |
chemokine (C-X-C motif) ligand 11 |
|
increases expression |
ISO |
4 |
76,954,835 |
76,957,350 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
affects expression |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
increases expression |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
increases expression |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
increases expression |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
increases expression |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL3 |
chemokine (C-X-C motif) ligand 3 |
|
affects expression |
ISO |
4 |
74,902,306 |
74,904,490 |
RGD:6480464 |
CTD |
| G |
CXCL5 |
chemokine (C-X-C motif) ligand 5 |
|
increases expression |
ISO |
4 |
74,861,359 |
74,864,416 |
RGD:6480464 |
CTD |
| G |
CXCL9 |
chemokine (C-X-C motif) ligand 9 |
|
affects expression |
ISO |
4 |
76,922,623 |
76,928,641 |
RGD:6480464 |
CTD |
| G |
CXCL9 |
chemokine (C-X-C motif) ligand 9 |
|
increases expression |
ISO |
4 |
76,922,623 |
76,928,641 |
RGD:6480464 |
CTD |
| G |
CXCL9 |
chemokine (C-X-C motif) ligand 9 |
|
increases expression |
ISO |
4 |
76,922,623 |
76,928,641 |
RGD:6480464 |
CTD |
| G |
CXCL9 |
chemokine (C-X-C motif) ligand 9 |
|
increases expression |
ISO |
4 |
76,922,623 |
76,928,641 |
RGD:6480464 |
CTD |
| G |
CXCL9 |
chemokine (C-X-C motif) ligand 9 |
|
increases expression |
ISO |
4 |
76,922,623 |
76,928,641 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
multiple interactions |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
affects localization |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
decreases expression |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR6 |
chemokine (C-X-C motif) receptor 6 |
|
increases expression |
ISO |
3 |
45,984,973 |
45,989,845 |
RGD:6480464 |
CTD |
| G |
CXCR7 |
chemokine (C-X-C motif) receptor 7 |
|
increases expression |
ISO |
2 |
237,478,380 |
237,490,997 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
decreases activity |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
decreases activity |
ISO |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1B1 |
cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
decreases expression |
EXP |
2 |
38,294,746 |
38,303,323 |
RGD:6480464 |
CTD |
| G |
CYP2A13 |
cytochrome P450, family 2, subfamily A, polypeptide 13 |
|
decreases activity |
ISO |
19 |
41,594,356 |
41,602,100 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases expression |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases expression |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
affects hydroxylation |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
affects response to substance |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases hydroxylation |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases metabolic processing |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases response to substance |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases response to substance |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases activity |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases hydroxylation |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases metabolic processing |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases hydroxylation |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases metabolic processing |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases response to substance |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases hydroxylation |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases metabolic processing |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases activity |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2C18 |
cytochrome P450, family 2, subfamily C, polypeptide 18 |
|
increases activity |
EXP |
10 |
96,443,251 |
96,495,947 |
RGD:6480464 |
CTD |
| G |
CYP2C18 |
cytochrome P450, family 2, subfamily C, polypeptide 18 |
|
multiple interactions |
EXP |
10 |
96,443,251 |
96,495,947 |
RGD:6480464 |
CTD |
| G |
CYP2C18 |
cytochrome P450, family 2, subfamily C, polypeptide 18 |
|
increases response to substance |
EXP |
10 |
96,443,251 |
96,495,947 |
RGD:6480464 |
CTD |
| G |
CYP2C18 |
cytochrome P450, family 2, subfamily C, polypeptide 18 |
|
increases metabolic processing |
ISO |
10 |
96,443,251 |
96,495,947 |
RGD:6480464 |
CTD |
| G |
CYP2C19 |
cytochrome P450, family 2, subfamily C, polypeptide 19 |
|
decreases metabolic processing |
EXP |
10 |
96,522,463 |
96,612,671 |
RGD:6480464 |
CTD |
| G |
CYP2C19 |
cytochrome P450, family 2, subfamily C, polypeptide 19 |
|
affects response to substance |
EXP |
10 |
96,522,463 |
96,612,671 |
RGD:6480464 |
CTD |
| G |
CYP2C19 |
cytochrome P450, family 2, subfamily C, polypeptide 19 |
|
increases metabolic processing |
EXP |
10 |
96,522,463 |
96,612,671 |
RGD:6480464 |
CTD |
| G |
CYP2C19 |
cytochrome P450, family 2, subfamily C, polypeptide 19 |
|
increases activity |
EXP |
10 |
96,522,463 |
96,612,671 |
RGD:6480464 |
CTD |
| G |
CYP2C19 |
cytochrome P450, family 2, subfamily C, polypeptide 19 |
|
multiple interactions |
EXP |
10 |
96,522,463 |
96,612,671 |
RGD:6480464 |
CTD |
| G |
CYP2C8 |
cytochrome P450, family 2, subfamily C, polypeptide 8 |
|
increases activity |
EXP |
10 |
96,796,529 |
96,829,254 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases metabolic processing |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases response to substance |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases activity |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
multiple interactions |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases expression |
ISO |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases metabolic processing |
ISO |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
decreases activity |
ISO |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2D6 |
cytochrome P450, family 2, subfamily D, polypeptide 6 |
|
increases metabolic processing |
EXP |
22 |
42,522,501 |
42,526,883 |
RGD:6480464 |
CTD |
| G |
CYP2E1 |
cytochrome P450, family 2, subfamily E, polypeptide 1 |
|
increases metabolic processing |
ISO |
10 |
135,340,867 |
135,352,620 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
ISO |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
affects response to substance |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
affects metabolic processing |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases metabolic processing |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
decreases activity |
ISO |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A5 |
cytochrome P450, family 3, subfamily A, polypeptide 5 |
|
affects metabolic processing |
EXP |
7 |
99,245,813 |
99,277,621 |
RGD:6480464 |
CTD |
| G |
CYP3A5 |
cytochrome P450, family 3, subfamily A, polypeptide 5 |
|
affects response to substance |
EXP |
7 |
99,245,813 |
99,277,621 |
RGD:6480464 |
CTD |
| G |
CYP3A5 |
cytochrome P450, family 3, subfamily A, polypeptide 5 |
|
multiple interactions |
EXP |
7 |
99,245,813 |
99,277,621 |
RGD:6480464 |
CTD |
| G |
DCN |
decorin |
|
multiple interactions |
ISO |
12 |
91,539,035 |
91,576,806 |
RGD:6480464 |
CTD |
| G |
DDB1 |
damage-specific DNA binding protein 1, 127kDa |
|
increases expression |
ISO |
11 |
61,066,919 |
61,100,684 |
RGD:6480464 |
CTD |
| G |
DDIT3 |
DNA-damage-inducible transcript 3 |
|
affects expression |
ISO |
12 |
57,910,371 |
57,914,300 |
RGD:6480464 |
CTD |
| G |
DDIT4 |
DNA-damage-inducible transcript 4 |
|
affects response to substance |
EXP |
10 |
74,033,677 |
74,035,797 |
RGD:6480464 |
CTD |
| G |
DLC1 |
deleted in liver cancer 1 |
|
increases expression |
EXP |
8 |
12,940,872 |
13,372,429 |
RGD:6480464 |
CTD |
| G |
DNAJB1 |
DnaJ (Hsp40) homolog, subfamily B, member 1 |
|
affects expression |
ISO |
19 |
14,625,582 |
14,629,201 |
RGD:6480464 |
CTD |
| G |
DNAJB6 |
DnaJ (Hsp40) homolog, subfamily B, member 6 |
|
increases expression |
EXP |
7 |
157,129,710 |
157,210,133 |
RGD:6480464 |
CTD |
| G |
DNMT1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
multiple interactions |
EXP |
19 |
10,244,022 |
10,305,755 |
RGD:6480464 |
CTD |
| G |
DNMT1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
decreases methylation |
EXP |
19 |
10,244,022 |
10,305,755 |
RGD:6480464 |
CTD |
| G |
DNMT1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
increases expression |
EXP |
19 |
10,244,022 |
10,305,755 |
RGD:6480464 |
CTD |
| G |
DNTT |
deoxynucleotidyltransferase, terminal |
|
decreases expression |
ISO |
10 |
98,064,085 |
98,098,321 |
RGD:6480464 |
CTD |
| G |
DPYSL4 |
dihydropyrimidinase-like 4 |
|
increases expression |
EXP |
10 |
134,000,414 |
134,019,280 |
RGD:6480464 |
CTD |
| G |
DRD1 |
dopamine receptor D1 |
|
affects binding |
ISO |
5 |
174,867,675 |
174,871,163 |
RGD:6480464 |
CTD |
| G |
DRD2 |
dopamine receptor D2 |
|
affects binding |
ISO |
11 |
113,280,317 |
113,346,001 |
RGD:6480464 |
CTD |
| G |
DSCR6 |
Down syndrome critical region gene 6 |
|
increases expression |
EXP |
21 |
38,378,863 |
38,391,959 |
RGD:6480464 |
CTD |
| G |
DUSP2 |
dual specificity phosphatase 2 |
|
decreases expression |
ISO |
2 |
96,808,908 |
96,811,179 |
RGD:6480464 |
CTD |
| G |
DZIP1 |
DAZ interacting protein 1 |
|
increases expression |
EXP |
13 |
96,230,456 |
96,296,960 |
RGD:6480464 |
CTD |
| G |
E2F3 |
E2F transcription factor 3 |
|
multiple interactions |
EXP |
6 |
20,402,137 |
20,493,945 |
RGD:6480464 |
CTD |
| G |
EDA2R |
ectodysplasin A2 receptor |
|
increases expression |
EXP |
X |
65,815,479 |
65,859,140 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
increases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
increases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDNRB |
endothelin receptor type B |
|
increases expression |
EXP |
13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 |
CTD |
| G |
EEF2 |
eukaryotic translation elongation factor 2 |
|
decreases expression |
ISO |
19 |
3,976,054 |
3,985,461 |
RGD:6480464 |
CTD |
| G |
EGFR |
epidermal growth factor receptor |
|
multiple interactions |
EXP |
7 |
55,086,725 |
55,275,031 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
increases expression |
EXP |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
increases expression |
ISO |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
decreases expression |
ISO |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
increases expression |
ISO |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR2 |
early growth response 2 |
|
decreases expression |
ISO |
10 |
64,571,756 |
64,578,927 |
RGD:6480464 |
CTD |
| G |
EIF1AX |
eukaryotic translation initiation factor 1A, X-linked |
|
multiple interactions |
EXP |
X |
20,142,636 |
20,159,966 |
RGD:6480464 |
CTD |
| G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
EXP |
8 |
37,888,020 |
37,917,883 |
RGD:6480464 |
CTD |
| G |
ELOVL2 |
ELOVL fatty acid elongase 2 |
|
affects response to substance |
EXP |
6 |
10,980,992 |
11,044,624 |
RGD:6480464 |
CTD |
| G |
EMP1 |
epithelial membrane protein 1 |
|
increases expression |
EXP |
12 |
13,349,602 |
13,369,708 |
RGD:6480464 |
CTD |
| G |
EMP3 |
epithelial membrane protein 3 |
|
increases expression |
EXP |
19 |
48,828,629 |
48,833,810 |
RGD:6480464 |
CTD |
| G |
EPB41L2 |
erythrocyte membrane protein band 4.1-like 2 |
|
decreases expression |
EXP |
6 |
131,160,487 |
131,384,462 |
RGD:6480464 |
CTD |
| G |
EPHX1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
affects expression |
ISO |
1 |
225,997,797 |
226,033,264 |
RGD:6480464 |
CTD |
| G |
EPHX1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
increases expression |
ISO |
1 |
225,997,797 |
226,033,264 |
RGD:6480464 |
CTD |
| G |
EPO |
erythropoietin |
|
multiple interactions |
ISO |
7 |
100,318,423 |
100,321,323 |
RGD:6480464 |
CTD |
| G |
EPO |
erythropoietin |
|
decreases expression |
ISO |
7 |
100,318,423 |
100,321,323 |
RGD:6480464 |
CTD |
| G |
EPO |
erythropoietin |
|
increases response to substance |
ISO |
7 |
100,318,423 |
100,321,323 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
EXP |
17 |
37,844,393 |
37,884,915 |
RGD:6480464 |
CTD |
| G |
ERBB4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
multiple interactions |
EXP |
2 |
212,240,442 |
213,403,352 |
RGD:6480464 |
CTD |
| G |
ERCC1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) |
|
affects expression |
ISO |
19 |
45,910,591 |
45,927,177 |
RGD:6480464 |
CTD |
| G |
ERCC2 |
excision repair cross-complementing rodent repair deficiency, complementation group 2 |
|
affects expression |
ISO |
19 |
45,854,649 |
45,873,845 |
RGD:6480464 |
CTD |
| G |
ERCC2 |
excision repair cross-complementing rodent repair deficiency, complementation group 2 |
|
affects expression |
ISO |
19 |
45,854,649 |
45,873,845 |
RGD:6480464 |
CTD |
| G |
ERCC2 |
excision repair cross-complementing rodent repair deficiency, complementation group 2 |
|
affects expression |
ISO |
19 |
45,854,649 |
45,873,845 |
RGD:6480464 |
CTD |
| G |
ERG |
v-ets erythroblastosis virus E26 oncogene homolog (avian) |
|
increases expression |
EXP |
21 |
39,739,183 |
40,033,704 |
RGD:6480464 |
CTD |
| G |
ESR1 |
estrogen receptor 1 |
|
multiple interactions |
EXP |
6 |
152,011,631 |
152,424,409 |
RGD:6480464 |
CTD |
| G |
ESR2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
EXP |
14 |
64,693,751 |
64,805,268 |
RGD:6480464 |
CTD |
| G |
F2RL1 |
coagulation factor II (thrombin) receptor-like 1 |
|
increases expression |
ISO |
5 |
76,114,833 |
76,131,140 |
RGD:6480464 |
CTD |
| G |
F2RL2 |
coagulation factor II (thrombin) receptor-like 2 |
|
increases expression |
ISO |
5 |
75,911,307 |
75,919,259 |
RGD:6480464 |
CTD |
| G |
F2RL3 |
coagulation factor II (thrombin) receptor-like 3 |
|
increases expression |
ISO |
19 |
16,999,826 |
17,002,830 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
decreases expression |
EXP |
1 |
94,994,732 |
95,007,413 |
RGD:6480464 |
CTD |
| G |
FAM19A5 |
family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 |
|
increases expression |
ISO |
22 |
48,885,288 |
49,147,744 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
EXP |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
EXP |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
EXP |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FASLG |
Fas ligand (TNF superfamily, member 6) |
|
multiple interactions |
EXP |
1 |
172,628,185 |
172,636,013 |
RGD:6480464 |
CTD |
| G |
FAU |
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed |
|
increases expression |
ISO |
11 |
64,888,099 |
64,889,672 |
RGD:6480464 |
CTD |
| G |
FCER1G |
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide |
|
increases expression |
ISO |
1 |
161,185,087 |
161,189,038 |
RGD:6480464 |
CTD |
| G |
FCGR2A |
Fc fragment of IgG, low affinity IIa, receptor (CD32) |
|
increases expression |
ISO |
1 |
161,475,205 |
161,489,360 |
RGD:6480464 |
CTD |
| G |
FCGRT |
Fc fragment of IgG, receptor, transporter, alpha |
|
increases expression |
ISO |
19 |
50,015,536 |
50,029,685 |
RGD:6480464 |
CTD |
| G |
FKBP1B |
FK506 binding protein 1B, 12.6 kDa |
|
affects response to substance |
EXP |
2 |
24,272,584 |
24,286,551 |
RGD:6480464 |
CTD |
| G |
FKBPL |
FK506 binding protein like |
|
increases expression |
EXP |
6 |
32,096,484 |
32,098,067 |
RGD:6480464 |
CTD |
| G |
FLNC |
filamin C, gamma |
|
increases expression |
EXP |
7 |
128,470,483 |
128,499,328 |
RGD:6480464 |
CTD |
| G |
FLT3LG |
fms-related tyrosine kinase 3 ligand |
|
affects expression |
ISO |
19 |
49,977,466 |
49,989,488 |
RGD:6480464 |
CTD |
| G |
FNDC3B |
fibronectin type III domain containing 3B |
|
affects response to substance |
EXP |
3 |
171,757,418 |
172,118,493 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOXP3 |
forkhead box P3 |
|
decreases expression |
ISO |
X |
49,106,897 |
49,121,288 |
RGD:6480464 |
CTD |
| G |
FPR2 |
formyl peptide receptor 2 |
|
increases expression |
ISO |
19 |
52,264,453 |
52,273,779 |
RGD:6480464 |
CTD |
| G |
FPR2 |
formyl peptide receptor 2 |
|
increases expression |
ISO |
19 |
52,264,453 |
52,273,779 |
RGD:6480464 |
CTD |
| G |
FSCN1 |
fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) |
|
increases expression |
EXP |
7 |
5,632,436 |
5,646,287 |
RGD:6480464 |
CTD |
| G |
FSHB |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
EXP |
11 |
30,252,563 |
30,256,824 |
RGD:6480464 |
CTD |
| G |
FYN |
FYN oncogene related to SRC, FGR, YES |
|
increases expression |
EXP |
6 |
111,981,535 |
112,194,655 |
RGD:6480464 |
CTD |
| G |
G3BP1 |
GTPase activating protein (SH3 domain) binding protein 1 |
|
decreases expression |
ISO |
5 |
151,151,476 |
151,184,915 |
RGD:6480464 |
CTD |
| G |
G6PC2 |
glucose-6-phosphatase, catalytic, 2 |
|
decreases expression |
ISO |
2 |
169,757,750 |
169,766,510 |
RGD:6480464 |
CTD |
| G |
GADD45A |
growth arrest and DNA-damage-inducible, alpha |
|
increases expression |
ISO |
1 |
68,150,860 |
68,154,021 |
RGD:6480464 |
CTD |
| G |
GADD45A |
growth arrest and DNA-damage-inducible, alpha |
|
affects expression |
ISO |
1 |
68,150,860 |
68,154,021 |
RGD:6480464 |
CTD |
| G |
GAL |
galanin/GMAP prepropeptide |
|
affects expression |
ISO |
11 |
68,451,983 |
68,458,643 |
RGD:6480464 |
CTD |
| G |
GAL |
galanin/GMAP prepropeptide |
|
increases expression |
ISO |
11 |
68,451,983 |
68,458,643 |
RGD:6480464 |
CTD |
| G |
GAL |
galanin/GMAP prepropeptide |
|
affects expression |
ISO |
11 |
68,451,983 |
68,458,643 |
RGD:6480464 |
CTD |
| G |
GALC |
galactosylceramidase |
|
affects response to substance |
EXP |
14 |
88,399,358 |
88,460,009 |
RGD:6480464 |
CTD |
| G |
GAMT |
guanidinoacetate N-methyltransferase |
|
multiple interactions |
EXP |
19 |
1,397,025 |
1,401,569 |
RGD:6480464 |
CTD |
| G |
GAP43 |
growth associated protein 43 |
|
increases expression |
ISO |
3 |
115,342,151 |
115,440,334 |
RGD:6480464 |
CTD |
| G |
GAP43 |
growth associated protein 43 |
|
increases expression |
ISO |
3 |
115,342,151 |
115,440,334 |
RGD:6480464 |
CTD |
| G |
GAS2 |
growth arrest-specific 2 |
|
increases expression |
EXP |
11 |
22,688,160 |
22,834,547 |
RGD:6480464 |
CTD |
| G |
GATA3 |
GATA binding protein 3 |
|
decreases expression |
ISO |
10 |
8,096,667 |
8,117,164 |
RGD:6480464 |
CTD |
| G |
GBP1 |
guanylate binding protein 1, interferon-inducible |
|
increases expression |
ISO |
1 |
89,517,987 |
89,531,043 |
RGD:6480464 |
CTD |
| G |
GBP3 |
guanylate binding protein 3 |
|
increases expression |
ISO |
1 |
89,472,360 |
89,488,549 |
RGD:6480464 |
CTD |
| G |
GDNF |
glial cell derived neurotrophic factor |
|
increases expression |
ISO |
5 |
37,812,779 |
37,839,782 |
RGD:6480464 |
CTD |
| G |
GEM |
GTP binding protein overexpressed in skeletal muscle |
|
increases expression |
ISO |
8 |
95,261,481 |
95,274,547 |
RGD:6480464 |
CTD |
| G |
GFI1 |
growth factor independent 1 transcription repressor |
|
decreases expression |
ISO |
1 |
92,940,318 |
92,952,433 |
RGD:6480464 |
CTD |
| G |
GFRA1 |
GDNF family receptor alpha 1 |
|
multiple interactions |
EXP |
10 |
117,816,436 |
118,033,126 |
RGD:6480464 |
CTD |
| G |
GJA1 |
gap junction protein, alpha 1, 43kDa |
|
affects expression |
ISO |
6 |
121,756,745 |
121,770,873 |
RGD:6480464 |
CTD |
| G |
GJB1 |
gap junction protein, beta 1, 32kDa |
|
decreases expression |
ISO |
X |
70,435,062 |
70,445,065 |
RGD:6480464 |
CTD |
| G |
GLOD4 |
glyoxalase domain containing 4 |
|
decreases expression |
EXP |
17 |
662,549 |
685,571 |
RGD:6480464 |
CTD |
| G |
GLRB |
glycine receptor, beta |
|
increases expression |
EXP |
4 |
157,997,277 |
158,093,242 |
RGD:6480464 |
CTD |
| G |
GLS |
glutaminase |
|
increases expression |
EXP |
2 |
191,745,547 |
191,830,278 |
RGD:6480464 |
CTD |
| G |
GLS |
glutaminase |
|
affects response to substance |
EXP |
2 |
191,745,547 |
191,830,278 |
RGD:6480464 |
CTD |
| G |
GNG12 |
guanine nucleotide binding protein (G protein), gamma 12 |
|
increases expression |
EXP |
1 |
68,167,149 |
68,299,155 |
RGD:6480464 |
CTD |
| G |
GPR137B |
G protein-coupled receptor 137B |
|
increases expression |
EXP |
1 |
236,305,832 |
236,372,209 |
RGD:6480464 |
CTD |
| G |
GPR20 |
G protein-coupled receptor 20 |
|
increases expression |
EXP |
8 |
142,366,585 |
142,377,365 |
RGD:6480464 |
CTD |
| G |
GPX3 |
glutathione peroxidase 3 (plasma) |
|
increases expression |
ISO |
5 |
150,399,999 |
150,408,554 |
RGD:6480464 |
CTD |
| G |
GPX4 |
glutathione peroxidase 4 |
|
increases expression |
EXP |
19 |
1,103,936 |
1,106,787 |
RGD:6480464 |
CTD |
| G |
GSR |
glutathione reductase |
|
multiple interactions |
ISO |
8 |
30,535,578 |
30,585,486 |
RGD:6480464 |
CTD |
| G |
GSR |
glutathione reductase |
|
multiple interactions |
ISO |
8 |
30,535,578 |
30,585,486 |
RGD:6480464 |
CTD |
| G |
GSR |
glutathione reductase |
|
decreases activity |
ISO |
8 |
30,535,578 |
30,585,486 |
RGD:6480464 |
CTD |
| G |
GSTA1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
EXP |
6 |
52,656,178 |
52,668,664 |
RGD:6480464 |
CTD |
| G |
GSTM1 |
glutathione S-transferase mu 1 |
|
multiple interactions |
EXP |
1 |
110,230,418 |
110,236,367 |
RGD:6480464 |
CTD |
| G |
GSTM2 |
glutathione S-transferase mu 2 (muscle) |
|
decreases expression |
ISO |
1 |
110,210,644 |
110,226,619 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
multiple interactions |
EXP |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
multiple interactions |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
affects response to substance |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
decreases response to substance |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
increases expression |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
increases expression |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GSTP1 |
glutathione S-transferase pi 1 |
|
increases expression |
ISO |
11 |
67,351,066 |
67,354,124 |
RGD:6480464 |
CTD |
| G |
GTF3C1 |
general transcription factor IIIC, polypeptide 1, alpha 220kDa |
|
multiple interactions |
EXP |
16 |
27,471,934 |
27,561,251 |
RGD:6480464 |
CTD |
| G |
GUSB |
glucuronidase, beta |
|
decreases expression |
ISO |
7 |
65,425,671 |
65,447,301 |
RGD:6480464 |
CTD |
| G |
GZMA |
granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) |
|
decreases expression |
ISO |
5 |
54,398,474 |
54,406,080 |
RGD:6480464 |
CTD |
| G |
GZMB |
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) |
|
increases expression |
ISO |
14 |
25,100,160 |
25,103,432 |
RGD:6480464 |
CTD |
| G |
HCRT |
hypocretin (orexin) neuropeptide precursor |
|
affects localization |
ISO |
17 |
40,336,078 |
40,337,470 |
RGD:6480464 |
CTD |
| G |
HCRT |
hypocretin (orexin) neuropeptide precursor |
|
decreases expression |
ISO |
17 |
40,336,078 |
40,337,470 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
increases expression |
ISO |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HLA-F |
major histocompatibility complex, class I, F |
|
increases expression |
EXP |
6 |
29,691,117 |
29,695,073 |
RGD:6480464 |
CTD |
| G |
HM13 |
histocompatibility (minor) 13 |
|
decreases expression |
ISO |
20 |
30,102,241 |
30,157,370 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
affects expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
decreases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
decreases expression |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
decreases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX2 |
heme oxygenase (decycling) 2 |
|
decreases expression |
ISO |
16 |
4,524,719 |
4,560,348 |
RGD:6480464 |
CTD |
| G |
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
|
increases expression |
EXP |
9 |
86,582,998 |
86,595,569 |
RGD:6480464 |
CTD |
| G |
HOXA1 |
homeobox A1 |
|
affects response to substance |
EXP |
7 |
27,132,612 |
27,135,625 |
RGD:6480464 |
CTD |
| G |
HPRT1 |
hypoxanthine phosphoribosyltransferase 1 |
|
increases mutagenesis |
ISO |
X |
133,594,175 |
133,634,698 |
RGD:6480464 |
CTD |
| G |
HSP90AA1 |
heat shock protein 90kDa alpha (cytosolic), class A member 1 |
|
decreases expression |
ISO |
14 |
102,547,075 |
102,606,086 |
RGD:6480464 |
CTD |
| G |
HSP90AB1 |
heat shock protein 90kDa alpha (cytosolic), class B member 1 |
|
decreases expression |
ISO |
6 |
44,214,849 |
44,221,614 |
RGD:6480464 |
CTD |
| G |
HSP90B1 |
heat shock protein 90kDa beta (Grp94), member 1 |
|
decreases expression |
ISO |
12 |
104,324,112 |
104,341,708 |
RGD:6480464 |
CTD |
| G |
HSP90B1 |
heat shock protein 90kDa beta (Grp94), member 1 |
|
increases expression |
ISO |
12 |
104,324,112 |
104,341,708 |
RGD:6480464 |
CTD |
| G |
HSPA1A |
heat shock 70kDa protein 1A |
|
affects expression |
ISO |
6 |
31,783,291 |
31,785,719 |
RGD:6480464 |
CTD |
| G |
HSPA1A |
heat shock 70kDa protein 1A |
|
increases expression |
EXP |
6 |
31,783,291 |
31,785,719 |
RGD:6480464 |
CTD |
| G |
HSPA1B |
heat shock 70kDa protein 1B |
|
affects expression |
ISO |
6 |
31,795,512 |
31,798,031 |
RGD:6480464 |
CTD |
| G |
HSPA1B |
heat shock 70kDa protein 1B |
|
decreases expression |
ISO |
6 |
31,795,512 |
31,798,031 |
RGD:6480464 |
CTD |
| G |
HSPA2 |
heat shock 70kDa protein 2 |
|
affects response to substance |
EXP |
14 |
65,007,186 |
65,009,955 |
RGD:6480464 |
CTD |
| G |
HSPA2 |
heat shock 70kDa protein 2 |
|
increases expression |
ISO |
14 |
65,007,186 |
65,009,955 |
RGD:6480464 |
CTD |
| G |
HSPA5 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
decreases expression |
ISO |
9 |
127,997,127 |
128,003,666 |
RGD:6480464 |
CTD |
| G |
HSPA8 |
heat shock 70kDa protein 8 |
|
affects response to substance |
EXP |
11 |
122,928,200 |
122,932,901 |
RGD:6480464 |
CTD |
| G |
HSPA9 |
heat shock 70kDa protein 9 (mortalin) |
|
decreases expression |
ISO |
5 |
137,890,571 |
137,911,318 |
RGD:6480464 |
CTD |
| G |
HSPB1 |
heat shock 27kDa protein 1 |
|
decreases expression |
ISO |
7 |
75,931,875 |
75,933,614 |
RGD:6480464 |
CTD |
| G |
HSPB1 |
heat shock 27kDa protein 1 |
|
increases expression |
ISO |
7 |
75,931,875 |
75,933,614 |
RGD:6480464 |
CTD |
| G |
HSPB1 |
heat shock 27kDa protein 1 |
|
increases expression |
ISO |
7 |
75,931,875 |
75,933,614 |
RGD:6480464 |
CTD |
| G |
HSPD1 |
heat shock 60kDa protein 1 (chaperonin) |
|
decreases expression |
ISO |
2 |
198,351,308 |
198,364,998 |
RGD:6480464 |
CTD |
| G |
HSPE1 |
heat shock 10kDa protein 1 (chaperonin 10) |
|
decreases expression |
ISO |
2 |
198,364,721 |
198,368,187 |
RGD:6480464 |
CTD |
| G |
HYOU1 |
hypoxia up-regulated 1 |
|
decreases expression |
ISO |
11 |
118,914,896 |
118,927,925 |
RGD:6480464 |
CTD |
| G |
ICA1 |
islet cell autoantigen 1, 69kDa |
|
affects response to substance |
ISO |
7 |
8,152,814 |
8,302,185 |
RGD:6480464 |
CTD |
| G |
ICAM1 |
intercellular adhesion molecule 1 |
|
affects response to substance |
ISO |
19 |
10,381,517 |
10,397,291 |
RGD:6480464 |
CTD |
| G |
ICAM3 |
intercellular adhesion molecule 3 |
|
decreases expression |
EXP |
19 |
10,444,452 |
10,450,345 |
RGD:6480464 |
CTD |
| G |
IER5 |
immediate early response 5 |
|
increases expression |
EXP |
1 |
181,057,638 |
181,059,979 |
RGD:6480464 |
CTD |
| G |
IFI16 |
interferon, gamma-inducible protein 16 |
|
increases expression |
ISO |
1 |
158,979,682 |
159,024,945 |
RGD:6480464 |
CTD |
| G |
IFIT2 |
interferon-induced protein with tetratricopeptide repeats 2 |
|
increases expression |
ISO |
10 |
91,061,706 |
91,069,033 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
affects expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
decreases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
increases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
multiple interactions |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
increases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
decreases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
increases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
increases expression |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNGR1 |
interferon gamma receptor 1 |
|
decreases expression |
ISO |
6 |
137,518,621 |
137,540,567 |
RGD:6480464 |
CTD |
| G |
IGF2BP3 |
insulin-like growth factor 2 mRNA binding protein 3 |
|
affects response to substance |
EXP |
7 |
23,349,828 |
23,509,995 |
RGD:6480464 |
CTD |
| G |
IGFBP3 |
insulin-like growth factor binding protein 3 |
|
affects response to substance |
EXP |
7 |
45,951,844 |
45,960,871 |
RGD:6480464 |
CTD |
| G |
IGFBP3 |
insulin-like growth factor binding protein 3 |
|
decreases expression |
ISO |
7 |
45,951,844 |
45,960,871 |
RGD:6480464 |
CTD |
| G |
IGFBP4 |
insulin-like growth factor binding protein 4 |
|
multiple interactions |
EXP |
17 |
38,599,676 |
38,613,982 |
RGD:6480464 |
CTD |
| G |
IGFBP5 |
insulin-like growth factor binding protein 5 |
|
decreases expression |
ISO |
2 |
217,536,828 |
217,560,272 |
RGD:6480464 |
CTD |
| G |
IGFBP5 |
insulin-like growth factor binding protein 5 |
|
decreases expression |
EXP |
2 |
217,536,828 |
217,560,272 |
RGD:6480464 |
CTD |
| G |
IGJ |
immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides |
|
decreases expression |
ISO |
4 |
71,521,258 |
71,532,348 |
RGD:6480464 |
CTD |
| G |
IGKC |
immunoglobulin kappa constant |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
IL10 |
interleukin 10 |
|
decreases expression |
ISO |
1 |
206,940,948 |
206,945,839 |
RGD:6480464 |
CTD |
| G |
IL10 |
interleukin 10 |
|
increases expression |
ISO |
1 |
206,940,948 |
206,945,839 |
RGD:6480464 |
CTD |
| G |
IL10 |
interleukin 10 |
|
increases expression |
ISO |
1 |
206,940,948 |
206,945,839 |
RGD:6480464 |
CTD |
| G |
IL10 |
interleukin 10 |
|
increases expression |
ISO |
1 |
206,940,948 |
206,945,839 |
RGD:6480464 |
CTD |
| G |
IL12B |
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) |
|
affects expression |
ISO |
5 |
158,741,791 |
158,757,481 |
RGD:6480464 |
CTD |
| G |
IL12B |
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) |
|
increases expression |
ISO |
5 |
158,741,791 |
158,757,481 |
RGD:6480464 |
CTD |
| G |
IL12B |
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) |
|
increases expression |
ISO |
5 |
158,741,791 |
158,757,481 |
RGD:6480464 |
CTD |
| G |
IL13RA1 |
interleukin 13 receptor, alpha 1 |
|
increases expression |
ISO |
X |
117,861,559 |
117,928,496 |
RGD:6480464 |
CTD |
| G |
IL13RA1 |
interleukin 13 receptor, alpha 1 |
|
increases expression |
ISO |
X |
117,861,559 |
117,928,496 |
RGD:6480464 |
CTD |
| G |
IL15RA |
interleukin 15 receptor, alpha |
|
increases expression |
ISO |
10 |
5,994,334 |
6,020,150 |
RGD:6480464 |
CTD |
| G |
IL16 |
interleukin 16 |
|
decreases expression |
ISO |
15 |
81,489,219 |
81,605,104 |
RGD:6480464 |
CTD |
| G |
IL18 |
interleukin 18 (interferon-gamma-inducing factor) |
|
increases expression |
ISO |
11 |
112,013,974 |
112,034,840 |
RGD:6480464 |
CTD |
| G |
IL1A |
interleukin 1, alpha |
|
increases expression |
ISO |
2 |
113,531,492 |
113,542,971 |
RGD:6480464 |
CTD |
| G |
IL1A |
interleukin 1, alpha |
|
affects response to substance |
EXP |
2 |
113,531,492 |
113,542,971 |
RGD:6480464 |
CTD |
| G |
IL1A |
interleukin 1, alpha |
|
increases expression |
ISO |
2 |
113,531,492 |
113,542,971 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases response to substance |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1RN |
interleukin 1 receptor antagonist |
|
increases expression |
ISO |
2 |
113,875,470 |
113,891,593 |
RGD:6480464 |
CTD |
| G |
IL2 |
interleukin 2 |
|
increases expression |
ISO |
4 |
123,372,625 |
123,377,650 |
RGD:6480464 |
CTD |
| G |
IL2 |
interleukin 2 |
|
decreases expression |
ISO |
4 |
123,372,625 |
123,377,650 |
RGD:6480464 |
CTD |
| G |
IL2 |
interleukin 2 |
|
increases expression |
ISO |
4 |
123,372,625 |
123,377,650 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
increases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
decreases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
increases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
increases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
increases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL5 |
interleukin 5 (colony-stimulating factor, eosinophil) |
|
increases expression |
ISO |
5 |
131,877,136 |
131,879,214 |
RGD:6480464 |
CTD |
| G |
IL5 |
interleukin 5 (colony-stimulating factor, eosinophil) |
|
increases expression |
ISO |
5 |
131,877,136 |
131,879,214 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
multiple interactions |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
multiple interactions |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
ISO |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
ILF3 |
interleukin enhancer binding factor 3, 90kDa |
|
multiple interactions |
EXP |
19 |
10,764,937 |
10,803,095 |
RGD:6480464 |
CTD |
| G |
IRG1 |
immunoresponsive 1 homolog (mouse) |
|
increases expression |
ISO |
13 |
77,522,694 |
77,532,777 |
RGD:6480464 |
CTD |
| G |
IRG1 |
immunoresponsive 1 homolog (mouse) |
|
increases expression |
ISO |
13 |
77,522,694 |
77,532,777 |
RGD:6480464 |
CTD |
| G |
IRS1 |
insulin receptor substrate 1 |
|
multiple interactions |
EXP |
2 |
227,596,033 |
227,663,506 |
RGD:6480464 |
CTD |
| G |
ISG15 |
ISG15 ubiquitin-like modifier |
|
increases expression |
EXP |
1 |
948,847 |
949,920 |
RGD:6480464 |
CTD |
| G |
ITK |
IL2-inducible T-cell kinase |
|
decreases expression |
ISO |
5 |
156,607,907 |
156,682,109 |
RGD:6480464 |
CTD |
| G |
KBTBD11 |
kelch repeat and BTB (POZ) domain containing 11 |
|
decreases expression |
EXP |
8 |
1,922,044 |
1,955,109 |
RGD:6480464 |
CTD |
| G |
KCNQ4 |
potassium voltage-gated channel, KQT-like subfamily, member 4 |
|
decreases expression |
EXP |
1 |
41,249,684 |
41,306,124 |
RGD:6480464 |
CTD |
| G |
KDM1A |
lysine (K)-specific demethylase 1A |
|
multiple interactions |
EXP |
1 |
23,345,941 |
23,410,184 |
RGD:6480464 |
CTD |
| G |
KDM1A |
lysine (K)-specific demethylase 1A |
|
increases expression |
EXP |
1 |
23,345,941 |
23,410,184 |
RGD:6480464 |
CTD |
| G |
KDM4B |
lysine (K)-specific demethylase 4B |
|
multiple interactions |
EXP |
19 |
4,969,124 |
5,153,609 |
RGD:6480464 |
CTD |
| G |
KDR |
kinase insert domain receptor (a type III receptor tyrosine kinase) |
|
decreases expression |
ISO |
4 |
55,944,426 |
55,991,762 |
RGD:6480464 |
CTD |
| G |
KDR |
kinase insert domain receptor (a type III receptor tyrosine kinase) |
|
increases expression |
ISO |
4 |
55,944,426 |
55,991,762 |
RGD:6480464 |
CTD |
| G |
KIAA1467 |
KIAA1467 |
|
multiple interactions |
EXP |
12 |
13,197,315 |
13,236,383 |
RGD:6480464 |
CTD |
| G |
KIF3A |
kinesin family member 3A |
|
multiple interactions |
EXP |
5 |
132,028,323 |
132,073,265 |
RGD:6480464 |
CTD |
| G |
KITLG |
KIT ligand |
|
affects expression |
ISO |
12 |
88,886,570 |
88,974,250 |
RGD:6480464 |
CTD |
| G |
KITLG |
KIT ligand |
|
multiple interactions |
ISO |
12 |
88,886,570 |
88,974,250 |
RGD:6480464 |
CTD |
| G |
KITLG |
KIT ligand |
|
increases expression |
ISO |
12 |
88,886,570 |
88,974,250 |
RGD:6480464 |
CTD |
| G |
KLF13 |
Kruppel-like factor 13 |
|
decreases expression |
ISO |
15 |
31,619,083 |
31,670,102 |
RGD:6480464 |
CTD |
| G |
KLF2 |
Kruppel-like factor 2 (lung) |
|
increases expression |
ISO |
19 |
16,435,651 |
16,438,345 |
RGD:6480464 |
CTD |
| G |
KLF4 |
Kruppel-like factor 4 (gut) |
|
decreases response to substance |
EXP |
9 |
110,247,133 |
110,252,047 |
RGD:6480464 |
CTD |
| G |
KLF5 |
Kruppel-like factor 5 (intestinal) |
|
affects response to substance |
EXP |
13 |
73,633,142 |
73,651,676 |
RGD:6480464 |
CTD |
| G |
KRT8 |
keratin 8 |
|
decreases expression |
ISO |
12 |
53,290,971 |
53,343,650 |
RGD:6480464 |
CTD |
| G |
KRT80 |
keratin 80 |
|
increases expression |
EXP |
12 |
52,562,780 |
52,585,784 |
RGD:6480464 |
CTD |
| G |
LAMC2 |
laminin, gamma 2 |
|
increases expression |
EXP |
1 |
183,155,174 |
183,214,262 |
RGD:6480464 |
CTD |
| G |
LAT |
linker for activation of T cells |
|
decreases expression |
ISO |
16 |
28,996,147 |
29,002,104 |
RGD:6480464 |
CTD |
| G |
LCK |
lymphocyte-specific protein tyrosine kinase |
|
decreases expression |
ISO |
1 |
32,716,840 |
32,751,766 |
RGD:6480464 |
CTD |
| G |
LCN2 |
lipocalin 2 |
|
increases expression |
ISO |
9 |
130,911,732 |
130,915,734 |
RGD:6480464 |
CTD |
| G |
LCN2 |
lipocalin 2 |
|
multiple interactions |
ISO |
9 |
130,911,732 |
130,915,734 |
RGD:6480464 |
CTD |
| G |
LCN2 |
lipocalin 2 |
|
increases expression |
ISO |
9 |
130,911,732 |
130,915,734 |
RGD:6480464 |
CTD |
| G |
LCN2 |
lipocalin 2 |
|
increases expression |
ISO |
9 |
130,911,732 |
130,915,734 |
RGD:6480464 |
CTD |
| G |
LDHB |
lactate dehydrogenase B |
|
affects response to substance |
EXP |
12 |
21,788,275 |
21,810,789 |
RGD:6480464 |
CTD |
| G |
LEF1 |
lymphoid enhancer-binding factor 1 |
|
decreases expression |
ISO |
4 |
108,968,701 |
109,090,112 |
RGD:6480464 |
CTD |
| G |
LGALS1 |
lectin, galactoside-binding, soluble, 1 |
|
increases expression |
EXP |
22 |
38,071,613 |
38,075,809 |
RGD:6480464 |
CTD |
| G |
LGALS7 |
lectin, galactoside-binding, soluble, 7 |
|
increases expression |
EXP |
19 |
39,261,608 |
39,264,157 |
RGD:6480464 |
CTD |
| G |
LMNB1 |
lamin B1 |
|
multiple interactions |
EXP |
5 |
126,112,315 |
126,172,712 |
RGD:6480464 |
CTD |
| G |
LRMP |
lymphoid-restricted membrane protein |
|
decreases expression |
ISO |
12 |
25,205,181 |
25,261,269 |
RGD:6480464 |
CTD |
| G |
LSG1 |
large subunit GTPase 1 homolog (S. cerevisiae) |
|
decreases expression |
EXP |
3 |
194,361,517 |
194,393,206 |
RGD:6480464 |
CTD |
| G |
LTBR |
lymphotoxin beta receptor (TNFR superfamily, member 3) |
|
increases expression |
ISO |
12 |
6,484,534 |
6,500,737 |
RGD:6480464 |
CTD |
| G |
LTF |
lactotransferrin |
|
decreases expression |
ISO |
3 |
46,477,496 |
46,506,598 |
RGD:6480464 |
CTD |
| G |
MAGED1 |
melanoma antigen family D, 1 |
|
affects response to substance |
EXP |
X |
51,546,155 |
51,645,450 |
RGD:6480464 |
CTD |
| G |
MAGED4B |
melanoma antigen family D, 4B |
|
affects response to substance |
EXP |
X |
51,804,923 |
51,812,368 |
RGD:6480464 |
CTD |
| G |
MAOA |
monoamine oxidase A |
|
increases expression |
EXP |
X |
43,514,155 |
43,606,071 |
RGD:6480464 |
CTD |
| G |
MAP3K12 |
mitogen-activated protein kinase kinase kinase 12 |
|
affects expression |
ISO |
12 |
53,874,276 |
53,893,444 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases expression |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases expression |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
multiple interactions |
EXP |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
affects expression |
ISO |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
decreases expression |
ISO |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases expression |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK7 |
mitogen-activated protein kinase 7 |
|
multiple interactions |
ISO |
17 |
19,281,034 |
19,286,857 |
RGD:6480464 |
CTD |
| G |
MAPK7 |
mitogen-activated protein kinase 7 |
|
multiple interactions |
ISO |
17 |
19,281,034 |
19,286,857 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
5 |
179,660,594 |
179,719,071 |
RGD:6480464 |
CTD |
| G |
MAPT |
microtubule-associated protein tau |
|
multiple interactions |
EXP |
17 |
43,971,748 |
44,105,700 |
RGD:6480464 |
CTD |
| G |
MARCKS |
myristoylated alanine-rich protein kinase C substrate |
|
increases expression |
EXP |
6 |
114,178,527 |
114,184,652 |
RGD:6480464 |
CTD |
| G |
MCM5 |
minichromosome maintenance complex component 5 |
|
decreases expression |
ISO |
22 |
35,796,116 |
35,820,495 |
RGD:6480464 |
CTD |
| G |
MDFIC |
MyoD family inhibitor domain containing |
|
decreases expression |
EXP |
7 |
114,562,209 |
114,659,970 |
RGD:6480464 |
CTD |
| G |
MED13L |
mediator complex subunit 13-like |
|
multiple interactions |
EXP |
12 |
116,396,381 |
116,714,991 |
RGD:6480464 |
CTD |
| G |
MELK |
maternal embryonic leucine zipper kinase |
|
multiple interactions |
EXP |
9 |
36,572,859 |
36,677,680 |
RGD:6480464 |
CTD |
| G |
METRN |
meteorin, glial cell differentiation regulator |
|
multiple interactions |
EXP |
16 |
765,173 |
767,480 |
RGD:6480464 |
CTD |
| G |
MFGE8 |
milk fat globule-EGF factor 8 protein |
|
decreases expression |
ISO |
15 |
89,441,914 |
89,456,663 |
RGD:6480464 |
CTD |
| G |
MGMT |
O-6-methylguanine-DNA methyltransferase |
|
decreases expression |
EXP |
10 |
131,265,454 |
131,565,783 |
RGD:6480464 |
CTD |
| G |
MGMT |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
EXP |
10 |
131,265,454 |
131,565,783 |
RGD:6480464 |
CTD |
| G |
MGST1 |
microsomal glutathione S-transferase 1 |
|
decreases expression |
ISO |
12 |
16,500,076 |
16,530,123 |
RGD:6480464 |
CTD |
| G |
MIF |
macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
|
multiple interactions |
ISO |
22 |
24,236,565 |
24,237,409 |
RGD:6480464 |
CTD |
| G |
MLH1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
decreases expression |
ISO |
3 |
37,034,841 |
37,092,337 |
RGD:6480464 |
CTD |
| G |
MMP3 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
|
increases expression |
ISO |
11 |
102,706,528 |
102,714,342 |
RGD:6480464 |
CTD |
| G |
MPC2 |
mitochondrial pyruvate carrier 2 |
|
affects response to substance |
EXP |
1 |
167,885,913 |
167,906,307 |
RGD:6480464 |
CTD |
| G |
MPG |
N-methylpurine-DNA glycosylase |
|
affects expression |
ISO |
16 |
127,018 |
135,850 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
increases activity |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
multiple interactions |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
multiple interactions |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
increases activity |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
increases activity |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MPO |
myeloperoxidase |
|
increases activity |
ISO |
17 |
56,347,217 |
56,358,296 |
RGD:6480464 |
CTD |
| G |
MR1 |
major histocompatibility complex, class I-related |
|
increases expression |
EXP |
1 |
181,002,561 |
181,031,074 |
RGD:6480464 |
CTD |
| G |
MS4A3 |
membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) |
|
decreases expression |
EXP |
11 |
59,824,101 |
59,838,588 |
RGD:6480464 |
CTD |
| G |
MSH2 |
mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) |
|
decreases expression |
ISO |
2 |
47,630,206 |
47,710,367 |
RGD:6480464 |
CTD |
| G |
MSH2 |
mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) |
|
decreases expression |
ISO |
2 |
47,630,206 |
47,710,367 |
RGD:6480464 |
CTD |
| G |
MSH3 |
mutS homolog 3 (E. coli) |
|
decreases expression |
ISO |
5 |
79,950,467 |
80,172,634 |
RGD:6480464 |
CTD |
| G |
MUC13 |
mucin 13, cell surface associated |
|
increases expression |
ISO |
3 |
124,624,289 |
124,653,595 |
RGD:6480464 |
CTD |
| G |
MUCL1 |
mucin-like 1 |
|
affects expression |
ISO |
12 |
55,248,299 |
55,252,177 |
RGD:6480464 |
CTD |
| G |
MX2 |
myxovirus (influenza virus) resistance 2 (mouse) |
|
decreases expression |
EXP |
21 |
42,733,950 |
42,780,869 |
RGD:6480464 |
CTD |
| G |
MXI1 |
MAX interactor 1, dimerization protein |
|
affects response to substance |
EXP |
10 |
111,967,363 |
112,047,123 |
RGD:6480464 |
CTD |
| G |
MYH10 |
myosin, heavy chain 10, non-muscle |
|
affects response to substance |
EXP |
17 |
8,377,523 |
8,534,079 |
RGD:6480464 |
CTD |
| G |
NAIP |
NLR family, apoptosis inhibitory protein |
|
multiple interactions |
EXP |
5 |
70,264,310 |
70,320,941 |
RGD:6480464 |
CTD |
| G |
NAMPT |
nicotinamide phosphoribosyltransferase |
|
increases expression |
ISO |
7 |
105,888,731 |
105,925,638 |
RGD:6480464 |
CTD |
| G |
NASP |
nuclear autoantigenic sperm protein (histone-binding) |
|
increases expression |
ISO |
1 |
46,049,660 |
46,084,578 |
RGD:6480464 |
CTD |
| G |
NDUFS2 |
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase) |
|
decreases expression |
ISO |
1 |
161,169,105 |
161,184,185 |
RGD:6480464 |
CTD |
| G |
NETO2 |
neuropilin (NRP) and tolloid (TLL)-like 2 |
|
increases expression |
EXP |
16 |
47,115,431 |
47,177,936 |
RGD:6480464 |
CTD |
| G |
NFATC3 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 |
|
decreases expression |
ISO |
16 |
68,119,269 |
68,263,162 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
decreases expression |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
multiple interactions |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
multiple interactions |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
decreases expression |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
increases expression |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFKBIZ |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta |
|
increases expression |
ISO |
3 |
101,546,834 |
101,579,869 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
increases expression |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
decreases expression |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
increases expression |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
increases expression |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
increases expression |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NGFR |
nerve growth factor receptor |
|
increases expression |
ISO |
17 |
47,572,655 |
47,592,382 |
RGD:6480464 |
CTD |
| G |
NGFR |
nerve growth factor receptor |
|
increases expression |
ISO |
17 |
47,572,655 |
47,592,382 |
RGD:6480464 |
CTD |
| G |
NGFR |
nerve growth factor receptor |
|
increases expression |
ISO |
17 |
47,572,655 |
47,592,382 |
RGD:6480464 |
CTD |
| G |
NGFR |
nerve growth factor receptor |
|
increases expression |
ISO |
17 |
47,572,655 |
47,592,382 |
RGD:6480464 |
CTD |
| G |
NGFR |
nerve growth factor receptor |
|
increases expression |
ISO |
17 |
47,572,655 |
47,592,382 |
RGD:6480464 |
CTD |
| G |
NID1 |
nidogen 1 |
|
affects response to substance |
EXP |
1 |
236,139,130 |
236,228,481 |
RGD:6480464 |
CTD |
| G |
NKAIN1 |
Na+/K+ transporting ATPase interacting 1 |
|
multiple interactions |
EXP |
1 |
31,652,592 |
31,712,734 |
RGD:6480464 |
CTD |
| G |
NME1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
increases expression |
ISO |
17 |
49,230,920 |
49,239,450 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases activity |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases activity |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases activity |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases activity |
ISO |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
increases expression |
ISO |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
increases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
increases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
increases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
increases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
increases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
NPRL2 |
nitrogen permease regulator-like 2 (S. cerevisiae) |
|
decreases expression |
EXP |
3 |
50,384,919 |
50,388,486 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
decreases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
decreases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
decreases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases activity |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR1I3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
EXP |
1 |
161,199,456 |
161,208,000 |
RGD:6480464 |
CTD |
| G |
NRG1 |
neuregulin 1 |
|
increases expression |
EXP |
8 |
31,496,820 |
32,622,558 |
RGD:6480464 |
CTD |
| G |
NRP1 |
neuropilin 1 |
|
decreases expression |
ISO |
10 |
33,466,419 |
33,623,833 |
RGD:6480464 |
CTD |
| G |
NRP1 |
neuropilin 1 |
|
increases expression |
ISO |
10 |
33,466,419 |
33,623,833 |
RGD:6480464 |
CTD |
| G |
NRP2 |
neuropilin 2 |
|
increases expression |
ISO |
2 |
206,547,224 |
206,662,857 |
RGD:6480464 |
CTD |
| G |
NT5C2 |
5'-nucleotidase, cytosolic II |
|
increases expression |
EXP |
10 |
104,847,774 |
104,953,063 |
RGD:6480464 |
CTD |
| G |
NTF3 |
neurotrophin 3 |
|
increases expression |
ISO |
12 |
5,541,280 |
5,604,465 |
RGD:6480464 |
CTD |
| G |
NTF4 |
neurotrophin 4 |
|
increases expression |
ISO |
19 |
49,564,397 |
49,567,124 |
RGD:6480464 |
CTD |
| G |
NTRK1 |
neurotrophic tyrosine kinase, receptor, type 1 |
|
multiple interactions |
ISO |
1 |
156,785,542 |
156,851,642 |
RGD:6480464 |
CTD |
| G |
NTRK2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
multiple interactions |
ISO |
9 |
87,283,466 |
87,638,505 |
RGD:6480464 |
CTD |
| G |
ODC1 |
ornithine decarboxylase 1 |
|
increases expression |
ISO |
2 |
10,580,508 |
10,588,453 |
RGD:6480464 |
CTD |
| G |
OPN3 |
opsin 3 |
|
affects response to substance |
EXP |
1 |
241,756,452 |
241,803,701 |
RGD:6480464 |
CTD |
| G |
OSM |
oncostatin M |
|
affects expression |
ISO |
22 |
30,658,818 |
30,662,829 |
RGD:6480464 |
CTD |
| G |
P2RY2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
decreases expression |
EXP |
11 |
72,929,344 |
72,947,397 |
RGD:6480464 |
CTD |
| G |
PAIP1 |
poly(A) binding protein interacting protein 1 |
|
decreases expression |
EXP |
5 |
43,526,369 |
43,557,521 |
RGD:6480464 |
CTD |
| G |
PALM2-AKAP2 |
PALM2-AKAP2 readthrough |
|
increases expression |
EXP |
9 |
112,542,577 |
112,934,792 |
RGD:6480464 |
CTD |
| G |
PARD3 |
par-3 partitioning defective 3 homolog (C. elegans) |
|
decreases expression |
EXP |
10 |
34,398,488 |
35,104,253 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
decreases expression |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
EXP |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
increases expression |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
affects expression |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
increases expression |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
decreases expression |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
decreases expression |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PCSK2 |
proprotein convertase subtilisin/kexin type 2 |
|
decreases expression |
ISO |
20 |
17,206,752 |
17,465,223 |
RGD:6480464 |
CTD |
| G |
PDCD4 |
programmed cell death 4 (neoplastic transformation inhibitor) |
|
decreases expression |
EXP |
10 |
112,631,553 |
112,659,764 |
RGD:6480464 |
CTD |
| G |
PDIA3 |
protein disulfide isomerase family A, member 3 |
|
decreases expression |
ISO |
15 |
44,038,590 |
44,064,804 |
RGD:6480464 |
CTD |
| G |
PDIA4 |
protein disulfide isomerase family A, member 4 |
|
increases expression |
ISO |
7 |
148,700,154 |
148,725,782 |
RGD:6480464 |
CTD |
| G |
PHLDA2 |
pleckstrin homology-like domain, family A, member 2 |
|
increases expression |
EXP |
11 |
2,949,503 |
2,950,650 |
RGD:6480464 |
CTD |
| G |
PIGA |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
increases mutagenesis |
ISO |
X |
15,337,573 |
15,353,676 |
RGD:6480464 |
CTD |
| G |
PIGR |
polymeric immunoglobulin receptor |
|
increases expression |
ISO |
1 |
207,101,867 |
207,119,811 |
RGD:6480464 |
CTD |
| G |
PLA2G4A |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
increases expression |
ISO |
1 |
186,798,032 |
186,958,113 |
RGD:6480464 |
CTD |
| G |
PLAU |
plasminogen activator, urokinase |
|
increases expression |
EXP |
10 |
75,670,862 |
75,677,259 |
RGD:6480464 |
CTD |
| G |
PLOD1 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 |
|
multiple interactions |
EXP |
1 |
11,994,724 |
12,035,599 |
RGD:6480464 |
CTD |
| G |
PLOD3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
|
multiple interactions |
EXP |
7 |
100,849,258 |
100,861,011 |
RGD:6480464 |
CTD |
| G |
PMS1 |
PMS1 postmeiotic segregation increased 1 (S. cerevisiae) |
|
increases expression |
ISO |
2 |
190,648,811 |
190,742,355 |
RGD:6480464 |
CTD |
| G |
PMS2 |
PMS2 postmeiotic segregation increased 2 (S. cerevisiae) |
|
decreases expression |
ISO |
7 |
6,012,870 |
6,048,737 |
RGD:6480464 |
CTD |
| G |
PMS2 |
PMS2 postmeiotic segregation increased 2 (S. cerevisiae) |
|
decreases expression |
ISO |
7 |
6,012,870 |
6,048,737 |
RGD:6480464 |
CTD |
| G |
POLM |
polymerase (DNA directed), mu |
|
increases expression |
EXP |
7 |
44,111,846 |
44,122,129 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
increases expression |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
PON1 |
paraoxonase 1 |
|
increases activity |
ISO |
7 |
94,927,669 |
94,953,884 |
RGD:6480464 |
CTD |
| G |
POR |
P450 (cytochrome) oxidoreductase |
|
multiple interactions |
EXP |
7 |
75,544,420 |
75,616,173 |
RGD:6480464 |
CTD |
| G |
POR |
P450 (cytochrome) oxidoreductase |
|
multiple interactions |
EXP |
7 |
75,544,420 |
75,616,173 |
RGD:6480464 |
CTD |
| G |
POR |
P450 (cytochrome) oxidoreductase |
|
increases expression |
ISO |
7 |
75,544,420 |
75,616,173 |
RGD:6480464 |
CTD |
| G |
POSTN |
periostin, osteoblast specific factor |
|
decreases expression |
ISO |
13 |
38,136,719 |
38,172,981 |
RGD:6480464 |
CTD |
| G |
PRLR |
prolactin receptor |
|
decreases expression |
ISO |
5 |
35,048,861 |
35,230,823 |
RGD:6480464 |
CTD |
| G |
PROCR |
protein C receptor, endothelial |
|
increases expression |
EXP |
20 |
33,759,774 |
33,765,165 |
RGD:6480464 |
CTD |
| G |
PRSS3 |
protease, serine, 3 |
|
affects response to substance |
EXP |
9 |
33,750,464 |
33,799,229 |
RGD:6480464 |
CTD |
| G |
PRTN3 |
proteinase 3 |
|
decreases expression |
EXP |
19 |
840,985 |
848,175 |
RGD:6480464 |
CTD |
| G |
PSMA5 |
proteasome (prosome, macropain) subunit, alpha type, 5 |
|
increases expression |
EXP |
1 |
109,941,653 |
109,969,108 |
RGD:6480464 |
CTD |
| G |
PTCRA |
pre T-cell antigen receptor alpha |
|
decreases expression |
ISO |
6 |
42,883,727 |
42,893,576 |
RGD:6480464 |
CTD |
| G |
PTGER1 |
prostaglandin E receptor 1 (subtype EP1), 42kDa |
|
decreases expression |
ISO |
19 |
14,583,278 |
14,586,174 |
RGD:6480464 |
CTD |
| G |
PTGER4 |
prostaglandin E receptor 4 (subtype EP4) |
|
multiple interactions |
ISO |
5 |
40,680,032 |
40,693,837 |
RGD:6480464 |
CTD |
| G |
PTGER4 |
prostaglandin E receptor 4 (subtype EP4) |
|
increases expression |
ISO |
5 |
40,680,032 |
40,693,837 |
RGD:6480464 |
CTD |
| G |
PTGER4 |
prostaglandin E receptor 4 (subtype EP4) |
|
increases expression |
ISO |
5 |
40,680,032 |
40,693,837 |
RGD:6480464 |
CTD |
| G |
PTGES3 |
prostaglandin E synthase 3 (cytosolic) |
|
increases expression |
ISO |
12 |
57,057,125 |
57,082,078 |
RGD:6480464 |
CTD |
| G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
9 |
125,132,809 |
125,157,982 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
affects response to substance |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTP4A1 |
protein tyrosine phosphatase type IVA, member 1 |
|
increases expression |
ISO |
6 |
64,281,920 |
64,293,489 |
RGD:6480464 |
CTD |
| G |
PTPRC |
protein tyrosine phosphatase, receptor type, C |
|
decreases expression |
ISO |
1 |
198,608,098 |
198,726,605 |
RGD:6480464 |
CTD |
| G |
PURA |
purine-rich element binding protein A |
|
increases expression |
ISO |
5 |
139,493,708 |
139,499,001 |
RGD:6480464 |
CTD |
| G |
RAD50 |
RAD50 homolog (S. cerevisiae) |
|
increases expression |
ISO |
5 |
131,892,616 |
131,980,313 |
RGD:6480464 |
CTD |
| G |
RAD51 |
RAD51 homolog (S. cerevisiae) |
|
increases expression |
ISO |
15 |
40,987,327 |
41,024,356 |
RGD:6480464 |
CTD |
| G |
RAD51 |
RAD51 homolog (S. cerevisiae) |
|
decreases expression |
ISO |
15 |
40,987,327 |
41,024,356 |
RGD:6480464 |
CTD |
| G |
RAD54L |
RAD54-like (S. cerevisiae) |
|
decreases expression |
ISO |
1 |
46,713,367 |
46,744,145 |
RGD:6480464 |
CTD |
| G |
RAD54L |
RAD54-like (S. cerevisiae) |
|
decreases expression |
ISO |
1 |
46,713,367 |
46,744,145 |
RGD:6480464 |
CTD |
| G |
RAG1 |
recombination activating gene 1 |
|
decreases expression |
ISO |
11 |
36,589,563 |
36,601,312 |
RGD:6480464 |
CTD |
| G |
RAMP1 |
receptor (G protein-coupled) activity modifying protein 1 |
|
increases expression |
EXP |
2 |
238,768,187 |
238,820,756 |
RGD:6480464 |
CTD |
| G |
RAMP1 |
receptor (G protein-coupled) activity modifying protein 1 |
|
multiple interactions |
EXP |
2 |
238,768,187 |
238,820,756 |
RGD:6480464 |
CTD |
| G |
RARA |
retinoic acid receptor, alpha |
|
increases expression |
ISO |
17 |
38,465,423 |
38,513,895 |
RGD:6480464 |
CTD |
| G |
RBPMS |
RNA binding protein with multiple splicing |
|
increases expression |
EXP |
8 |
30,241,944 |
30,429,734 |
RGD:6480464 |
CTD |
| G |
REG3A |
regenerating islet-derived 3 alpha |
|
increases expression |
ISO |
2 |
79,384,132 |
79,386,880 |
RGD:6480464 |
CTD |
| G |
REG3A |
regenerating islet-derived 3 alpha |
|
increases expression |
ISO |
2 |
79,384,132 |
79,386,880 |
RGD:6480464 |
CTD |
| G |
REG3G |
regenerating islet-derived 3 gamma |
|
increases expression |
ISO |
2 |
79,252,812 |
79,255,630 |
RGD:6480464 |
CTD |
| G |
REG3G |
regenerating islet-derived 3 gamma |
|
increases expression |
ISO |
2 |
79,252,812 |
79,255,630 |
RGD:6480464 |
CTD |
| G |
REG3G |
regenerating islet-derived 3 gamma |
|
increases expression |
ISO |
2 |
79,252,812 |
79,255,630 |
RGD:6480464 |
CTD |
| G |
REG3G |
regenerating islet-derived 3 gamma |
|
increases expression |
ISO |
2 |
79,252,812 |
79,255,630 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases expression |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases expression |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
REV1 |
REV1, polymerase (DNA directed) |
|
decreases response to substance |
ISO |
2 |
100,016,938 |
100,106,480 |
RGD:6480464 |
CTD |
| G |
RNASE2 |
ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) |
|
decreases expression |
EXP |
14 |
21,423,630 |
21,424,594 |
RGD:6480464 |
CTD |
| G |
RPA1 |
replication protein A1, 70kDa |
|
decreases expression |
ISO |
17 |
1,733,273 |
1,802,848 |
RGD:6480464 |
CTD |
| G |
RPA2 |
replication protein A2, 32kDa |
|
decreases expression |
ISO |
1 |
28,218,049 |
28,241,236 |
RGD:6480464 |
CTD |
| G |
RPS3 |
ribosomal protein S3 |
|
decreases expression |
ISO |
11 |
75,110,535 |
75,133,346 |
RGD:6480464 |
CTD |
| G |
RPS6KA2 |
ribosomal protein S6 kinase, 90kDa, polypeptide 2 |
|
affects response to substance |
EXP |
6 |
166,822,854 |
167,275,771 |
RGD:6480464 |
CTD |
| G |
RRAGA |
Ras-related GTP binding A |
|
decreases expression |
EXP |
9 |
19,049,372 |
19,051,023 |
RGD:6480464 |
CTD |
| G |
RRAS2 |
related RAS viral (r-ras) oncogene homolog 2 |
|
increases expression |
EXP |
11 |
14,299,466 |
14,386,052 |
RGD:6480464 |
CTD |
| G |
RRM1 |
ribonucleotide reductase M1 |
|
decreases expression |
ISO |
11 |
4,115,924 |
4,160,106 |
RGD:6480464 |
CTD |
| G |
RRM2 |
ribonucleotide reductase M2 |
|
multiple interactions |
EXP |
2 |
10,262,695 |
10,271,546 |
RGD:6480464 |
CTD |
| G |
RRM2B |
ribonucleotide reductase M2 B (TP53 inducible) |
|
increases expression |
EXP |
8 |
103,216,729 |
103,251,346 |
RGD:6480464 |
CTD |
| G |
RTEL1 |
regulator of telomere elongation helicase 1 |
|
increases expression |
EXP |
20 |
62,289,163 |
62,327,606 |
RGD:6480464 |
CTD |
| G |
RUNX3 |
runt-related transcription factor 3 |
|
decreases expression |
EXP |
1 |
25,226,002 |
25,291,501 |
RGD:6480464 |
CTD |
| G |
S100P |
S100 calcium binding protein P |
|
decreases expression |
EXP |
4 |
6,695,566 |
6,698,897 |
RGD:6480464 |
CTD |
| G |
S100P |
S100 calcium binding protein P |
|
affects response to substance |
EXP |
4 |
6,695,566 |
6,698,897 |
RGD:6480464 |
CTD |
| G |
SAA2 |
serum amyloid A2 |
|
increases expression |
ISO |
11 |
18,259,780 |
18,270,221 |
RGD:6480464 |
CTD |
| G |
SALL1 |
sal-like 1 (Drosophila) |
|
affects response to substance |
EXP |
16 |
51,169,886 |
51,185,183 |
RGD:6480464 |
CTD |
| G |
SATB1 |
SATB homeobox 1 |
|
decreases expression |
ISO |
3 |
18,389,133 |
18,480,265 |
RGD:6480464 |
CTD |
| G |
SCG3 |
secretogranin III |
|
decreases expression |
ISO |
15 |
51,973,550 |
52,013,223 |
RGD:6480464 |
CTD |
| G |
SCUBE2 |
signal peptide, CUB domain, EGF-like 2 |
|
multiple interactions |
EXP |
11 |
9,041,047 |
9,113,150 |
RGD:6480464 |
CTD |
| G |
SFN |
stratifin |
|
increases expression |
EXP |
1 |
27,189,633 |
27,190,947 |
RGD:6480464 |
CTD |
| G |
SGCE |
sarcoglycan, epsilon |
|
affects response to substance |
EXP |
7 |
94,214,536 |
94,285,521 |
RGD:6480464 |
CTD |
| G |
SIT1 |
signaling threshold regulating transmembrane adaptor 1 |
|
decreases expression |
ISO |
9 |
35,649,295 |
35,650,947 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
decreases expression |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
|
increases expression |
EXP |
9 |
136,336,216 |
136,344,276 |
RGD:6480464 |
CTD |
| G |
SLIT1 |
slit homolog 1 (Drosophila) |
|
decreases expression |
EXP |
10 |
98,757,795 |
98,945,683 |
RGD:6480464 |
CTD |
| G |
SLPI |
secretory leukocyte peptidase inhibitor |
|
decreases expression |
ISO |
20 |
43,880,879 |
43,883,206 |
RGD:6480464 |
CTD |
| G |
SNX10 |
sorting nexin 10 |
|
increases expression |
ISO |
7 |
26,331,515 |
26,413,949 |
RGD:6480464 |
CTD |
| G |
SOAT1 |
sterol O-acyltransferase 1 |
|
affects response to substance |
EXP |
1 |
179,262,849 |
179,327,815 |
RGD:6480464 |
CTD |
| G |
SOCS1 |
suppressor of cytokine signaling 1 |
|
decreases expression |
ISO |
16 |
11,348,274 |
11,350,039 |
RGD:6480464 |
CTD |
| G |
SOCS7 |
suppressor of cytokine signaling 7 |
|
increases expression |
ISO |
17 |
36,508,007 |
36,561,846 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
increases expression |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
decreases expression |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
increases expression |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SPARC |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
decreases expression |
ISO |
5 |
151,040,657 |
151,066,615 |
RGD:6480464 |
CTD |
| G |
SPARC |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
increases expression |
EXP |
5 |
151,040,657 |
151,066,615 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
affects response to substance |
EXP |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
affects expression |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SRM |
spermidine synthase |
|
multiple interactions |
EXP |
1 |
11,114,649 |
11,120,091 |
RGD:6480464 |
CTD |
| G |
SSRP1 |
structure specific recognition protein 1 |
|
increases expression |
ISO |
11 |
57,093,459 |
57,103,351 |
RGD:6480464 |
CTD |
| G |
ST13 |
suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) |
|
increases expression |
ISO |
22 |
41,220,599 |
41,252,687 |
RGD:6480464 |
CTD |
| G |
ST14 |
suppression of tumorigenicity 14 (colon carcinoma) |
|
multiple interactions |
EXP |
11 |
130,029,682 |
130,080,257 |
RGD:6480464 |
CTD |
| G |
STAT1 |
signal transducer and activator of transcription 1, 91kDa |
|
increases expression |
ISO |
2 |
191,833,762 |
191,878,976 |
RGD:6480464 |
CTD |
| G |
STAT3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
increases phosphorylation |
ISO |
17 |
40,465,343 |
40,540,513 |
RGD:6480464 |
CTD |
| G |
STAT5B |
signal transducer and activator of transcription 5B |
|
decreases expression |
ISO |
17 |
40,351,195 |
40,428,424 |
RGD:6480464 |
CTD |
| G |
STIP1 |
stress-induced-phosphoprotein 1 |
|
decreases expression |
ISO |
11 |
63,953,587 |
63,972,020 |
RGD:6480464 |
CTD |
| G |
STIP1 |
stress-induced-phosphoprotein 1 |
|
decreases expression |
ISO |
11 |
63,953,587 |
63,972,020 |
RGD:6480464 |
CTD |
| G |
STK39 |
serine threonine kinase 39 |
|
multiple interactions |
EXP |
2 |
168,810,530 |
169,104,105 |
RGD:6480464 |
CTD |
| G |
STK4 |
serine/threonine kinase 4 |
|
decreases expression |
ISO |
20 |
43,595,120 |
43,708,594 |
RGD:6480464 |
CTD |
| G |
STMN3 |
stathmin-like 3 |
|
increases expression |
EXP |
20 |
62,271,061 |
62,284,780 |
RGD:6480464 |
CTD |
| G |
STOM |
stomatin |
|
increases expression |
EXP |
9 |
124,101,266 |
124,132,582 |
RGD:6480464 |
CTD |
| G |
TAC1 |
tachykinin, precursor 1 |
|
multiple interactions |
ISO |
7 |
97,361,271 |
97,369,784 |
RGD:6480464 |
CTD |
| G |
TAC1 |
tachykinin, precursor 1 |
|
affects expression |
ISO |
7 |
97,361,271 |
97,369,784 |
RGD:6480464 |
CTD |
| G |
TAC1 |
tachykinin, precursor 1 |
|
increases expression |
ISO |
7 |
97,361,271 |
97,369,784 |
RGD:6480464 |
CTD |
| G |
TAC1 |
tachykinin, precursor 1 |
|
increases secretion |
ISO |
7 |
97,361,271 |
97,369,784 |
RGD:6480464 |
CTD |
| G |
TAC1 |
tachykinin, precursor 1 |
|
increases expression |
ISO |
7 |
97,361,271 |
97,369,784 |
RGD:6480464 |
CTD |
| G |
TACR1 |
tachykinin receptor 1 |
|
multiple interactions |
ISO |
2 |
75,273,590 |
75,426,645 |
RGD:6480464 |
CTD |
| G |
TACR1 |
tachykinin receptor 1 |
|
increases expression |
ISO |
2 |
75,273,590 |
75,426,645 |
RGD:6480464 |
CTD |
| G |
TACR1 |
tachykinin receptor 1 |
|
decreases response to substance |
ISO |
2 |
75,273,590 |
75,426,645 |
RGD:6480464 |
CTD |
| G |
TAP1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
|
increases expression |
EXP |
6 |
32,812,986 |
32,821,748 |
RGD:6480464 |
CTD |
| G |
TAT |
tyrosine aminotransferase |
|
affects expression |
ISO |
16 |
71,600,754 |
71,610,998 |
RGD:6480464 |
CTD |
| G |
TAT |
tyrosine aminotransferase |
|
decreases expression |
ISO |
16 |
71,600,754 |
71,610,998 |
RGD:6480464 |
CTD |
| G |
TCF7 |
transcription factor 7 (T-cell specific, HMG-box) |
|
decreases expression |
ISO |
5 |
133,450,402 |
133,483,920 |
RGD:6480464 |
CTD |
| G |
TCP1 |
t-complex 1 |
|
decreases expression |
ISO |
6 |
160,199,530 |
160,210,735 |
RGD:6480464 |
CTD |
| G |
TCP1 |
t-complex 1 |
|
increases expression |
ISO |
6 |
160,199,530 |
160,210,735 |
RGD:6480464 |
CTD |
| G |
TEX30 |
testis expressed 30 |
|
decreases expression |
EXP |
13 |
103,418,460 |
103,426,149 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
affects expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases secretion |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFBR2 |
transforming growth factor, beta receptor II (70/80kDa) |
|
increases expression |
ISO |
3 |
30,647,994 |
30,735,634 |
RGD:6480464 |
CTD |
| G |
THBS1 |
thrombospondin 1 |
|
increases expression |
ISO |
15 |
39,873,280 |
39,889,668 |
RGD:6480464 |
CTD |
| G |
THBS1 |
thrombospondin 1 |
|
increases expression |
ISO |
15 |
39,873,280 |
39,889,668 |
RGD:6480464 |
CTD |
| G |
THBS1 |
thrombospondin 1 |
|
multiple interactions |
ISO |
15 |
39,873,280 |
39,889,668 |
RGD:6480464 |
CTD |
| G |
THNSL2 |
threonine synthase-like 2 (S. cerevisiae) |
|
multiple interactions |
EXP |
2 |
88,469,814 |
88,486,156 |
RGD:6480464 |
CTD |
| G |
THY1 |
Thy-1 cell surface antigen |
|
decreases expression |
ISO |
11 |
119,288,655 |
119,294,246 |
RGD:6480464 |
CTD |
| G |
TM4SF1 |
transmembrane 4 L six family member 1 |
|
increases expression |
EXP |
3 |
149,086,805 |
149,095,568 |
RGD:6480464 |
CTD |
| G |
TMED3 |
transmembrane emp24 protein transport domain containing 3 |
|
decreases expression |
ISO |
15 |
79,603,491 |
79,615,189 |
RGD:6480464 |
CTD |
| G |
TMEFF1 |
transmembrane protein with EGF-like and two follistatin-like domains 1 |
|
affects response to substance |
EXP |
9 |
103,235,520 |
103,339,918 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
affects expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
affects expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases response to substance |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
decreases response to substance |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNFAIP3 |
tumor necrosis factor, alpha-induced protein 3 |
|
increases expression |
EXP |
6 |
138,188,325 |
138,204,451 |
RGD:6480464 |
CTD |
| G |
TNFRSF14 |
tumor necrosis factor receptor superfamily, member 14 |
|
increases expression |
EXP |
1 |
2,487,805 |
2,495,268 |
RGD:6480464 |
CTD |
| G |
TNFRSF18 |
tumor necrosis factor receptor superfamily, member 18 |
|
decreases expression |
ISO |
1 |
1,138,888 |
1,142,089 |
RGD:6480464 |
CTD |
| G |
TNFSF9 |
tumor necrosis factor (ligand) superfamily, member 9 |
|
increases expression |
EXP |
19 |
6,531,010 |
6,535,939 |
RGD:6480464 |
CTD |
| G |
TNNI3 |
troponin I type 3 (cardiac) |
|
increases expression |
EXP |
19 |
55,663,135 |
55,669,100 |
RGD:6480464 |
CTD |
| G |
TNNI3 |
troponin I type 3 (cardiac) |
|
increases expression |
EXP |
19 |
55,663,135 |
55,669,100 |
RGD:6480464 |
CTD |
| G |
TOP2A |
topoisomerase (DNA) II alpha 170kDa |
|
multiple interactions |
EXP |
17 |
38,544,773 |
38,574,202 |
RGD:6480464 |
CTD |
| G |
TOP2A |
topoisomerase (DNA) II alpha 170kDa |
|
multiple interactions |
EXP |
17 |
38,544,773 |
38,574,202 |
RGD:6480464 |
CTD |
| G |
TOP2A |
topoisomerase (DNA) II alpha 170kDa |
|
increases expression |
ISO |
17 |
38,544,773 |
38,574,202 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
multiple interactions |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
affects response to substance |
EXP |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases mutagenesis |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
affects response to substance |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases mutagenesis |
EXP |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases activity |
EXP |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
multiple interactions |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases expression |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TPD52 |
tumor protein D52 |
|
decreases expression |
EXP |
8 |
80,947,103 |
81,083,836 |
RGD:6480464 |
CTD |
| G |
TPM1 |
tropomyosin 1 (alpha) |
|
affects response to substance |
EXP |
15 |
63,334,838 |
63,364,114 |
RGD:6480464 |
CTD |
| G |
TRPV1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
decreases expression |
ISO |
17 |
3,468,740 |
3,512,705 |
RGD:6480464 |
CTD |
| G |
TUBA4A |
tubulin, alpha 4a |
|
increases expression |
EXP |
2 |
220,115,001 |
220,118,638 |
RGD:6480464 |
CTD |
| G |
TUBB2B |
tubulin, beta 2B class IIb |
|
decreases expression |
ISO |
6 |
3,224,495 |
3,227,968 |
RGD:6480464 |
CTD |
| G |
TXNRD1 |
thioredoxin reductase 1 |
|
decreases activity |
ISO |
12 |
104,609,557 |
104,744,085 |
RGD:6480464 |
CTD |
| G |
TYMP |
thymidine phosphorylase |
|
multiple interactions |
EXP |
22 |
50,964,181 |
50,968,514 |
RGD:6480464 |
CTD |
| G |
TYROBP |
TYRO protein tyrosine kinase binding protein |
|
increases expression |
ISO |
19 |
36,395,303 |
36,399,211 |
RGD:6480464 |
CTD |
| G |
UBD |
ubiquitin D |
|
increases expression |
ISO |
6 |
29,523,389 |
29,527,702 |
RGD:6480464 |
CTD |
| G |
UNG |
uracil-DNA glycosylase |
|
decreases expression |
ISO |
12 |
109,535,399 |
109,548,798 |
RGD:6480464 |
CTD |
| G |
UPK1A |
uroplakin 1A |
|
decreases expression |
ISO |
19 |
36,157,715 |
36,169,367 |
RGD:6480464 |
CTD |
| G |
UPK1A |
uroplakin 1A |
|
decreases expression |
ISO |
19 |
36,157,715 |
36,169,367 |
RGD:6480464 |
CTD |
| G |
UPK1A |
uroplakin 1A |
|
multiple interactions |
ISO |
19 |
36,157,715 |
36,169,367 |
RGD:6480464 |
CTD |
| G |
UPK1B |
uroplakin 1B |
|
decreases expression |
ISO |
3 |
118,892,425 |
118,924,000 |
RGD:6480464 |
CTD |
| G |
UPK1B |
uroplakin 1B |
|
multiple interactions |
ISO |
3 |
118,892,425 |
118,924,000 |
RGD:6480464 |
CTD |
| G |
UPK1B |
uroplakin 1B |
|
decreases expression |
ISO |
3 |
118,892,425 |
118,924,000 |
RGD:6480464 |
CTD |
| G |
UPK2 |
uroplakin 2 |
|
decreases expression |
ISO |
11 |
118,827,008 |
118,829,269 |
RGD:6480464 |
CTD |
| G |
UPK2 |
uroplakin 2 |
|
multiple interactions |
ISO |
11 |
118,827,008 |
118,829,269 |
RGD:6480464 |
CTD |
| G |
UPK2 |
uroplakin 2 |
|
decreases expression |
ISO |
11 |
118,827,008 |
118,829,269 |
RGD:6480464 |
CTD |
| G |
UPK3A |
uroplakin 3A |
|
decreases expression |
ISO |
22 |
45,680,868 |
45,691,755 |
RGD:6480464 |
CTD |
| G |
UPK3A |
uroplakin 3A |
|
decreases expression |
ISO |
22 |
45,680,868 |
45,691,755 |
RGD:6480464 |
CTD |
| G |
UPK3A |
uroplakin 3A |
|
multiple interactions |
ISO |
22 |
45,680,868 |
45,691,755 |
RGD:6480464 |
CTD |
| G |
UPK3A |
uroplakin 3A |
|
decreases expression |
ISO |
22 |
45,680,868 |
45,691,755 |
RGD:6480464 |
CTD |
| G |
USP36 |
ubiquitin specific peptidase 36 |
|
increases expression |
EXP |
17 |
76,792,965 |
76,836,969 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
increases expression |
ISO |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
increases expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
affects expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VIM |
vimentin |
|
affects expression |
ISO |
10 |
17,270,258 |
17,279,592 |
RGD:6480464 |
CTD |
| G |
VIP |
vasoactive intestinal peptide |
|
multiple interactions |
ISO |
6 |
153,071,932 |
153,080,900 |
RGD:6480464 |
CTD |
| G |
VIP |
vasoactive intestinal peptide |
|
affects expression |
ISO |
6 |
153,071,932 |
153,080,900 |
RGD:6480464 |
CTD |
| G |
VIP |
vasoactive intestinal peptide |
|
affects response to substance |
ISO |
6 |
153,071,932 |
153,080,900 |
RGD:6480464 |
CTD |
| G |
VIP |
vasoactive intestinal peptide |
|
multiple interactions |
ISO |
6 |
153,071,932 |
153,080,900 |
RGD:6480464 |
CTD |
| G |
VIPR1 |
vasoactive intestinal peptide receptor 1 |
|
increases expression |
ISO |
3 |
42,530,791 |
42,579,065 |
RGD:6480464 |
CTD |
| G |
VIPR2 |
vasoactive intestinal peptide receptor 2 |
|
affects expression |
ISO |
7 |
158,820,866 |
158,937,649 |
RGD:6480464 |
CTD |
| G |
WAS |
Wiskott-Aldrich syndrome |
|
decreases expression |
ISO |
X |
48,542,186 |
48,549,818 |
RGD:6480464 |
CTD |
| G |
WAS |
Wiskott-Aldrich syndrome |
|
decreases expression |
ISO |
X |
48,542,186 |
48,549,818 |
RGD:6480464 |
CTD |
| G |
XIST |
X inactive specific transcript (non-protein coding) |
|
increases expression |
ISO |
X |
73,040,486 |
73,072,588 |
RGD:6480464 |
CTD |
| G |
XPC |
xeroderma pigmentosum, complementation group C |
|
affects expression |
ISO |
3 |
14,186,647 |
14,220,172 |
RGD:6480464 |
CTD |
| G |
XRCC1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
|
decreases expression |
ISO |
19 |
44,047,464 |
44,079,730 |
RGD:6480464 |
CTD |
| G |
XRCC6 |
X-ray repair complementing defective repair in Chinese hamster cells 6 |
|
decreases expression |
ISO |
22 |
42,017,295 |
42,060,052 |
RGD:6480464 |
CTD |
| G |
ZAP70 |
zeta-chain (TCR) associated protein kinase 70kDa |
|
decreases expression |
ISO |
2 |
98,330,031 |
98,356,323 |
RGD:6480464 |
CTD |
| G |
ZIC1 |
Zic family member 1 |
|
affects response to substance |
EXP |
3 |
147,127,181 |
147,134,506 |
RGD:6480464 |
CTD |
| G |
ZNF552 |
zinc finger protein 552 |
|
multiple interactions |
EXP |
19 |
58,318,450 |
58,326,281 |
RGD:6480464 |
CTD |
| G |
ZNF671 |
zinc finger protein 671 |
|
decreases expression |
EXP |
19 |
58,231,119 |
58,238,995 |
RGD:6480464 |
CTD |
Term paths to the root
|